Note: Descriptions are shown in the official language in which they were submitted.
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
~3-LACTAMASE INHIEITORS AND METHODS OF ITSE THEREOF
CR~SS REFERENCE TO RELATED APPLICATIONS
The present application claims priority under 35 U.S.C. ~ 119(e) of
provisional
application 60/477,636, filed June 10, 2003, which is hereby incorporated
herein by
reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to inhibitors of,~-lactamase and methods of
use thereof. Specifically, the invention relates to non-/3-lactam-based
inhibitors of (3-
lactamase.
PACI~~Il~OIJI~~TD ~F TIE Ii~TVEh~1'~"I~~T
Drug resistance to antibiotics, especially ~3-lactam antibiotics such as
penicillin, cephalosporin and related compounds is one of the most serious
problems in
the treatment of infectious diseases (Neu, SeierZCe, 257, 1064-1073 (1992)).
It represents
not only a significant medical problem but a major public health and economic
burden.
between 190 a~ld 1992, the death rate, due to infectious diseases as the
underlying
cause of death, increased 5~°/~, from 4.1 to 65 deaths per 100,000
population in the U.S.
~.ge adjusted mortality from infectious diseases increased 39°!'~ dux-
ing the saa~~e period.
Infectious disease morality increased 25°/~ among those aged 65 years
and older (from
271 to 33~ per 100,000) and 6.3 times among 25-44 year olds (from 6 to 3~ per
100,000). I~Iortality due to respiratory tract infections increased
20°f° (from 25 to 30
deaths per 100,000). lZeports from the Center for Disease Control (CI7C)
indicate that
two million Americans acquire infections in hospitals each year, the cost of
which runs
to an estimated $4.5 billion. Of these infections, 70% are due to microbes
that are
resistant to one or more antibiotics and in 30-40% of the infections the
causative microbe
is resistant to first line treatment. The rate at which patients acquire
infections in
-1-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hospitals rose by 36% in 1995 compared with 1975. In 1995, 35.9 million
patients
entered hospitals in the U.S. compared with 37.7 million patients in 1975. For
the same
period, lengths of hosptial stays dropped to an, average of 5.3 days from 7.9
days due to
managed health care guidelines. However, the number of infections per 1,000
patient
days rose to 9.77 from 7.18.
Without being limited to any particular theory or mechanism of action, it
is believed that evolutionary selection and genetic transformation have made
this
problem pressing. Most antibiotic drugs are derivatives of naturally occurring
bactericides (Davies, Science, 264, 375-382 (1994)), and many resistance
mechanisms
evolved long ago. Human use of antibiotics has refined these mechanisms and
promoted
their spread through gene transfer (Davies, Scief2ce, 264, 375-382 (1994)). A
resistance
mechanism originating in one species of bacteria can be expected to spread
throughout
the biosphere.
,6-lactam antibiotics inhibit bacterial cell wall biosynthesis (Tomasz, Rev.
Infect. I9is., 8, 5270-5278 (1986)). They form covalent complexes with and
consequently inactivate a group of transpeptidases/carboxypeptidases called
the
Penicillin )3inding Proteins (P>3Ps). PEP inactivation disrupts cell wall
biosynthesis,
leading to self lysis and death of the bacteria. ~-lactam antibiotics have
been widely
prescribed. In the absence of resistance, ~3-lactams are the first choice for
treatment in 45
of 78 common bacterial infections (Goodman ~z Gilman's The
.~lac~a~fnezc~l~~icr~l Rczsis ~f
They~czpezstics (Hardman et al., eds., MeGraw-Hill, New York, 1996)).
J3acterial adaptations to ,Q-lactam drugs (e.g., amoxicillin, cephalothin,
clavulanate, and a~treonam) are among the best studied and most pernicious
forms of
antibiotic resistance. Without being limited to any particular theory or
mechanism of
~~tion5 it is bel~e~ed that ba~,leria use see~eral clifferel~t ra~echar~~~nm
tea esc~.pe I°~ro~w ~'_
lactam antibiotics Ganders, Clivaicczl Iyafccti~us~ I~i~c~se, I4., 1089-1099
(1992) T.<i et al.,
Aizt'irzaicr~~Lz. A,~-etzt',r ~'lac~z~thei~., 39, 1948-1953 (1995)). Probably
the n post widespread
is the hydrolysis ~f,~-lactams by ~-lactamase enzymes.
~3-lactamases are endogenous bacterial enzymes that destroy ~3-lactam
antibiotics and eliminate their efficacy. The name derives from their ability
to cleave the
f3-lactam ring. The structures of many,-lactamases are known at the atomic
level and
available in the protein database. At least four classes of (3-lactamases are
known:
Glasses A, D, C and D. At the clinical level, the 111oSt important ~-
lactamases belong to
Class A (TENT) and Class C (AmpC). TEM and Amp-C are serine hydrolases and
have a
-2-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
critical serine in their catalytic site. TEM and AmpC) among different
bacterial species
share high sequence identity and structural similarity (Galleni, et al.,
Biochem. J., 250,
753-760 (1988); Galleni, et al., Biochem. J., 250, 753-760 (1988); Usher et
al.,
Biochemistry, 30, 16082-16092 (1998)).
One way to overcome the negative effects of (3-lactamases is to use
molecules that neutralize the action of,~-lactamase (known as ,~-lactamase
inhibitors or
inhibitors of,~-lactamase) in combination with antibiotics. The three ,Q-
lactamase
inhibitors currently in clinical use (clavulanic acid, sulbactam and
tazobactam) are all
transition state analogs that utilize the same ~3-lactam core that is present
in the
Z O antibiotics themselves.
The similarity between the ~3-lactam antibiotics and ~3-Iactam-based ~i-
lactamase inhibitors has proven to be a serious problem. Resistance to such (3-
lactam-
based ~3-lactamase inhibitors arises through modifications of previously
susceptible
mechanisms. Certain mutations in ,Q-lactamase, for example, reduce the
effectiveness of
15 ~3-lactam-based ~i-lactamase inhibitors while preserving the ability of the
(3-lactamase to
hydrolyze the antibiotic molecules. Certain point substitutions in (3-
lactamases allow the
enzymes to hydrolyze compounds designed to evade them (Philippon et al.,
Antimicrob.
~1~-e3zts Chemotlaei°., 33, 1131-1136 (1989)). ~ther substitutions
reduce the affinity of (3-
lactam inhibitors for the enzymes (Saves, et al., J: Biol, ClZem., 270, 18240-
18245
20 (1995)) or allow the enzymes to simply hydrolyze them. Furthermore, several
gram-
positive bacteria (e.g., Stapla. Aureus) have acquired sensor proteins that
detect ,Q-lactams
in the environment of the cell ()3ennet and Chopra, Antimierob. ~l~ents
Chemotherapy,
37, 153-158 (1993)). ~-lactam binding to these sensors leads to
transcriptional up-
regulation of the ,Q-lactamase. ,~-lactam-based ,~-lacta ease inhibitors,
thus, can induce
25 tlm laroclucti~n oaf the enzyme that they are nmant t~ iz~ahibit,
p~°eventing or a~ed~.~cia~g their
efficacy.
without being limited to any particular theor-~r or mechanism of action, it
is believed that one reason that bacteria have been able to respond rapidly
with "new"
resistance mechanisms to ,~-lactam-based inhibitors is that the mechanisms of
action of
30 the inhibitors axe not, in fact, new, because ~3-lactamases have evolved
mechanisms for,
e.g., sensing and/or hydrolyzing such molecules. Accordingly, as long as
medicinal
chemistry focuses on ,~-lactam-based molecules to overcome (~-lactamases,
resistance
can be expected to follow shortly.
-3-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
One way to avoid recapitulating this "arms race" between bacteria and ~i-
lactams is to develop non-(3-lactam inhibitors that have novel chemistries and
are
dissimilar to ~3-lactams. Such non-~i-lactam inhibitors would not themselves
be degraded
by ,Q-lactamases, and mutations in the enzymes would not be expected render
such
inhibitors labile to hydrolysis. Such novel inhibitors would also escape
detection by ~3-
lactam sensor proteins that up-regulate ,Q-lactamase transcription, and may be
unaffected
by porin mutations that limit the access of (3-lactams to PBPs. Such
inhibitors would
allow the current ~'-lactam antibiotics to effectively work against bacteria
where ~i-
lactamases provide the dominant resistance mechanism.
I O It has previously been reported that boric acid and certain phenyl boronic
acids are inhibitors of certain (3-lactamases (I~oehler and Lienhard, (1971);
Kiener and
Waley, Bioclaena. J., 169, 197-204 (1978) (boric acid, phenylboronic acid and
m-
aminophenylboronate); Beesley et al., Biochem. J., 209, 229-233 (I983) (twelve
substituted phenylborinic acids, including 2-fonnylphenylboronate, 4-
formylphenylboronate, and 4-methylphenylboronate; and Amicosante et al., J.
Claef~zot7aerczpy, l, 394-398 (1989) (boric acid, phenylboronic acid, m-
azninophenylboronate and tetraphenylboronic acid)). m-(dansylamidophenyl)-
boronic
acid has been reported to inhibitor of the E'zate~~bactes° el~czca~ P99
,Q-lactamase
(I~ryjanslci and Pratt, Bi~chemistry, 34, 3561-3568 (1995)). In addition,
Strynadl~a and
colleagues used the crystallographic structure of a mutant TEh~I-1 enzyme-
penicillin C"a
complex to design a novel alkylboronic acid inhibitor [(1R)-1-acetamido-2-(3-
carboxyphenyl)ethane boronic acid] with high affinity for this enzyme.
(Strynadka et al.,
Nezt. AftYUC. Bi~l., 3, 688-695 (1996)).
t~dditional boronic acid-based compounds with demonstrated or potential
ability tea ~nhlbit b-lactaznase~ 12a~,~e laeen repzaz-ted in ~"~ndi et al.
(~'l~~aa~i~i~d~a ~ .~a~al~~,
8, 593-610 (2001), I~lartin et al. (Bio~ag~cz~cic c~. l~~dicizaccl G'h~~~is~ay
Le~t~~s, 4.(I0),
1229-1234 (1994), Weston et al. (J: I~rle~. ~'la~f~a., 4.1, 4577-x.586 (1998)
and jJ.S. Patents
1lTo. 6,075,014 and 6,184,363
Many of the compounds described above are peptide derivatives or
peptidyl mimetics which are not desirable as orally available pharmaceutical
drugs due to
their rapid degradation by digestive enzymes (Ness et al, 2000; Morandi et al,
2003,
Rudgers et al, 2001).
-4-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Hence, there remains a need for new non-~i-lactarn-based ,Q-lactamase
inhibitors that are active against a wide variety of ~3-Iactamases,
particularly those that
are resistant to clavulanic acid, sulbactam and tazobactam.
Citation or identification of any references in the "Background of the
Invention" or anywhere in the specification of this application is not an
admission that
such references available as prior art to the present invention.
SUMMARY OF THE INVENTION
The present invention provides compounds having the formula (A):
(HO)2-B-T (A)
wherein
B stands for boron, and
T has one of the following structures:
R,o
R"
,
Re
Ro wry
/~ ~ R~
/' R~ R~ ~ \(~
(III)
R3 ~X\1°/~~
Re R~ ~ R7
9 ,
-5-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
R~
R~
(VI)
0
(VII)
(ix) (x) \
N
\ o
(XI)
p HOOC ~ Ri
a
(XII)
-6-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Rt
R2
Ra
(XIV)
R~
and
2
(xV)
Wherein RI through RIZ are each independently
(i) when connected t~ a carbon atom: hydrogen, C1_G alkyl, C3_6
cycloallcyl, C1_3 alkoxy, rz-butoxy, i-butoxy, sec-butoXy, R13R14N- (Wherein
R~3 and Rl~
are each independently hydrogen or Cl_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoXy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitr~,
carboXyl,
C1_~ allcoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloXy, hydroxyl,
trimethylsilyloXy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -CH~, -CH=I~T~H,
C=N~HCH3, -S~3H, -S~2CH3, -S~zNHRIS,Wherein Rls is hydrogen or C1_3 allcyl, or
~(CHz)"~R1G-9 ~yherein R16 is hydrogen or C1.3 alkyl, and n is 1, 2 or 3; or
When any tWo
T~;s are located at the ~~~t~z~ position to each other, they together Form -
~;_~,~-~,~=~4._
(Wlxerein ~ 1 through ~4 each independently represents CH or 1~T), -S-C~-C-, -
CH=CH-
l~lI~-, -CH=CH-S-, -CH=CH-~-, -1'~T=CH-~TH-, -CHI-1~T=I~T-, -hT--t~T-~-, -
~T=CSI-S- or -~-
CH2CH~-~-;
or
(ii) When connected to a nitrogen atom: absent;
X, Y and Z are each independently carbon or nitrogen;
and
Q is oxygen or lone-pair electrons.
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
In a first embodiment, the compounds of the present invention are
represented by formula A(I):
~R6 A(I)
\R
wherein
RI through R9 are each independently
(i) when connected to a carbon atom: hydrogen, C1_6 alkyl, C3_s
cycloalkyl, CI_3 alkoxy, fZ-butoxy, i.-butoxy, sec-butoxy, RI3RI4N-,wherein
RI3 and RIB.
are each independently hydrogen or Cl_3 alkyl, trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitro,
carboxyl,
CI_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -CHO, -CH=NOH,
C=NOHCH3, -SO3H, -SOzCH3, -SOzNHRls,whermn R;5 is hydrogen or CI_3 alkyl, or -
O(CHz)"ORI6-,wherein R;6 is hydrogen or CI_3 alkyl, and n is 1, 2 or 3; or
when any two
R;s are located at the ~~th~ position to each other, they together form -~I=~2-
~3'~4',
wherein ~I through ~4 each independently represents CH or N, -S-C~-O-, -CH=CH-
NH-,
-CH=CH-S-, -CH=CHO-, -N=CH-NH-, -CHz-N=IV-, -N=N-O-, -N=CH-S- or -O-
CHzCHz-~-; or
(ii) when connected to a nitrogen atom: absent;
and
~, ~y and ~ are each independently carbon or nitrogen.
In a. preferred embodiment of the first embodiment,
R;, R~ and ~, are each hydrogen;
Rz is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, utro,
carboxyl, CI_4 allcoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -SOz,CH3 and -SOzNHz;
RS is:
(i) when ~ is nitrogen:
absent, and
_g_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(ii) when X is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro,
brorno, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4 alkoxycarbonyl,
phenyl,
phenoxy, phenoxycarbonyl, 2, 4-dichlorophenoxy, benzyloxy, hydroxyl,
hydroxymethyl,
-CHO, -CH=NOH, -C--NOHCH3, -S03H, -SOZCH3, -S~2NH2, or when RS are located
at the ortho position to another R;, they together form -ZI=ZZ-Z3=Z4- (wherein
Zl
through Z4 each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -
CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-
CHZCH2-O-;
R6 is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -SO3H, -SO2CH3, -SO~NHa, or when R~ are located at the
o~tho position to another R;, they together foam -~,1=~2-~3=~4- (wherein ~1
through ~4
each independently represents CH or N), -S-C~-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CHz-O-;
R7 is:
(i) when ~ is nitrogen:
absent, and
(ii) when ~ is carbon:
'?5 hydrogeay C;_a alh;rl, C~_~ cyclo~lhyl, ~'1_; allko~~~~~
trifhaoro~~aethyl~ fl~boro,
chl~ro, bromo, cyano, acetyl, amino, borono, nitr~, carbo~~yl, Cl_4
alkoxycarbonyl,
phenyl, plmnoxy, pheno~~ycarbonyl, ben~yloxy, hydro~~yl, hydro~~~nethyl, -CHO,
_
CH=NOH, -C=NOHCH3, -SO~H, -S~~CH~, -SOzI~TH2, or when Its are locsted at the
oy~tho position to another R;, they together form ~;=~2-~3°~4- (wherein
~r through ~4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CHaCHa-O-;
R8 through R9 are each independently hydrogen, CI_4. alkyl, G3-6
cycloallcyl, C1_3 all~oxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, nitro, carboxyl, CI_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
-9-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
benzyloxy, hydroxyl, hydroxymethyl, -CHO, -CH--NOH, -C=NOHCH3, -S03H, -
S02CH3, -SO2NH2, or when any two R;s are located at the o~tho position to each
other,
they together form -~I=~2-~3=~4- (wherein ZI through Z4 each independently
represents
CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-
N=N-, -N N-O-, -N=CH-S- or -O-CHaCH2-O-; and
X, Y and Z are each independently carbon or nitrogen.
In a second embodiment, the compounds of the present invention are
represented by formula A(II):
Rio
R11
A(II)
wherein RI through RIZ are each independently hydrogen, CI_6 alkyl, C3_6
cycloalleyl, CI_3 alkoxy, n-butoxy, z-butoxy, see-butoxy, RI3RI4N- (wherein
RI3 and RIq
are each independently hydrogen or Cl_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, aa111n~, borono, nitro,
carboxyl,
C1_6 allcoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SOZCH3,
SOzNHRIS (wherein RIS is hydrogen or C1_3 alkyl), or -O(CHZ)nORl6- (wherein
R;6 is
hydrogen gar ~'I_3 alkyl, and n is l, 2 or 3~; or v~hen any two R;s are
located at the ~v~~la~
position to each other, they together form -~I=~2-~3=~4- (wherein GI through
~4 each
independently represents CH or ~T), -S-C~-O-, -CH=CH-1~H-, -CH=CH-S-, -CH=CH-O-
,
-~T=CH-1~~I-, -CHI-N=N-, -hr ~T-O-, -IV=CH-S- or -O-CI-IZCHz-O-.
In a preferred embodiment of the second embodiment,
RI, R3, R4, R9, RI I and RI2 are each hydrogen;
R2 and RIO are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, nitro, amino, borono, carboxyl, CI_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-SO3H, -SOzCH3 and -S~2NH?;
-10-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
RS through R8 are each independently hydrogen, C1_4 alkyl, C3_s
cycloalkyl, Ci_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -S03H, -SOZCH3, -SOzNHz, or when any two
R;s
are located at the os°tho position to each other, they together form -
Zl=Zz-Z3-Za-
(wherein Zl through Z4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N N-, -N=N-O-, -N=CH-S- or -O-
CHZCHz-O-.
Tn a third embodiment, the compounds of the present invention are
represented by formula A(III):
R,
z
A(III)
Y
Rs
wherein R1 through R9 are each independently
(i) when connected to a carbon atom:
hydrogen, C1_s alkyl, C3_s cycloalkyl, C1_3 alkoxy, ya-butoxy, i-butoxy, s~c-
butoxy, RI3R14N- (wherein R13 and R14 are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, vitro, carboxyl, C1_s alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
ben~yloxy, hydro~~yl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-~.'H=1~1K:~~h -C=1~TOI-IC~I~, -SO~~I, -~"Oz~'F-I~, -SOzhTFIRIS (~fherean p~z~
is la~,~drogen or
C1_3 alkyl), or -O(CHz)"ORIS- (wherein Rls is hydrogen or C1_3 alkyl, and n is
1, 2 or 3);
or when any two R;s are located at the ~ay~t'~iea position to each other, they
together forlm -
~1=~Z'~3=~4.- (wherein Zl through Z~. each independently represents CH or hT),
-S-CO
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, _
N=CH-S- or -O-CHzCHz-O-; or
(ii) when connected to a nitrogen atom;
absent;
and
N, ~ and Z are each independently carbon or nitrogen.
-11-
K3 R5
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
In a preferred embodiment of the third embodiment,
Rl, R3 and R4 are each hydrogen;
R2 is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carboxyl, C1_4 alkoxycarbonyl, phenoxycaxbonyl, hydxoxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -SO2CH3 and -SO2NH2;
RS is:
(i) when X is nitrogen:
absent, and
(ii) when X is carbon:
r 10 hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl,
fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benayloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=N~HCH3, -S03H, -S02CH3, -S~ZNHZ, or when RS axe located at the
ortlao position to another R;, they together form -Zi=Zz-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O=, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N N-O-, -N=CH-S- or -O-CH2CH2-O-;
R6 is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, CI_~. alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydxoxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=N~HCH3, -S03H, -S~ZCH3, -SOzN.EI2, or when R6 are located at the
~drr~~ca position t~ smother 1'~;, theyr together 1°~aran -~i=~2-~~=~,a-
(~~~~lmrain ~ 1 tl~~,bagl~a ~r
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-~-, -hT=CH-~)~I-, -CH2-N=N-, -N=N~O-, -N=CH-S~ or -O-CH~CI~2-O-;
R7 is:
(i) when ~ is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, Ci_4 alkyl, C3_6 cycloallcyl, C1_3 alkoxy, trifluoxomethyl, fluoro,
chloxo, bronco, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycaxbonyl,
phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl, hydroxymethyl, -CHO, -
_1~_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
CH=NOH, -C=NOHCH3, -S03H, -SOZCH3, -SOzNHz, or when R7 are located at the
of~tho position to another R;, they together form -Zl=Zz-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCHz-O-;
R$ through R9 are each independently hydrogen, C1_4 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, nitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -CHO, -CH-NOH, -C--NOHCH3,-S03H, -SOaCH3,
-SOzNHz, or when any two R;s are located at the ortho position to each other,
they
together form -Zl=Zz-Z3=Z4- (wherein Zl through Z4 each independently
represents CH
or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -
N=N-O-, -N=CH-S- or -O-CH2CHz-O-; and
X, Y and Z are each independently carbon or nitrogen.
In one particular embodiment of the third embodiment, the present
invention relates to compounds represented by formula A(III)
wherein Rl through R9 are each independently
(i) when connected to a carbon atom:
hydrogen, C1_6 alkyl, C3_g cycloalkyl, CI_3 alkoxy, ~z-butoxy, i-butoxy, see-
butoxy, RI3R14N- (wherein R13 and R14. are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, nitro, carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -S~zCH3, -SOzNHRIS (wherein Rls is hydrogen or
CI_3 alkyl), or -O(CHz)"OR1G- (wherein R16 is hydrogen or C1_3 alkyl, and n is
1, 2 or 3);
2a or wheat an;r two I~;s ~.re 1~cate~, at the oi~~.~~~z position to each
other they t~ogethex form -
Zi=Zz-Z3=Za- (wherein Zl through Z4 each independently represents CH or N), -S-
CO-
O-P -CH=CH-NH-9 -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-hT=hT-, -l~T=N-O-, -
N=CH-S- or -O-CHzCHz-O-; or
(ii) when comzected to a nitrogen atom:
absent;
and
X, Y and Z are each independently carbon or nitrogen;
with the proviso that
-13-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
when Rl=R3=R.~=RS=R6=R7=R8=R9=hydrogen, and X=Y=Z=carbon; Ra
is not NH2, NO2,, or H.
In another embodiment of the third embodiment, the invention relates to
compounds described by formula A(III) wherein
Rl, R3 and R4 are each hydrogen;
Rz is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carboxyl, Ci_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -SOzCH3 and -SO2NH2;
R51S:
(i) when X is nitrogen:
absent, and
(ii) when X is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloallcyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -SOzCH3, -S~2NH2, or when RS are located at the
~r~tlao position to another R;, they together form -Zl=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHa-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-;
R6 is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloallcyl, Ci_3 alkoxy, trifluoromethyl, fluoro,
~,5 chloro~ bron X09 c~ragm, acet~rl, aminoa borono~ nitro, carbonyl, Cr_4
alko~~yc~rbonyl,
phenyl, pheno~~y, phenoxycarbonyl, benzyloxy, hydroxyl, hydro~cyrrmthyl, -CHO,
_
CH=NOH, -C=NOHCH3, -SO~H, -SOZCH~, -SOZ1~~I2, or when R6 ire located at the
~~~la~ position to another R;, they together form -Z1=Z~-Zs=Z4- (wherein Z;
through G~
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N N-, -N N-O-, -N=CH-S- or -O-CHaCH2-O-;
R7 is:
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
-14-
......,,..,.. ....... .~.~,~"r.~.,in r~~.
~nnnnnunnnuiunnmmnunnnnmnunnonvmmnniinnnnn 1
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -S~zCH3, -SOzNHz, or when R7 are located at the
o~tlao position to another R;, they together form -Zl=Zz-Z3=Z4- (wherein Z;
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N N-, -N=N-O-, -N=CH-S- or -O-CH2CHz-O-;
R8 through R9 are each independently hydrogen, C1_~ alkyl, C3_6
cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, Cl_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -CHO, -CH-NOH, -C=NOHCH3,-S03H, -SOzCH3,
-SOzNHz, or when any two R;s are located at the ortho position to each other,
they
together form -Zi=Zz-Z3=Zq- (wherein Z; through Z4 each independently
represents CH
or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -
N=N-O-, -N=CH-S- or -O-CH2CHz-O-; and
X, Y and Z are each independently carbon or nitrogen;
with the proviso that
when Rt= R3= R~= RS= R6= R7= R8= R9=hydrogen, and ~=Y=Z=carbon;
Rz is not NHz, NOz,, or H.
In a fourth embodiment, the compounds of the present invention are
represented by formula A(I~):
,~(zv)
g
. ~z
~r
wherein Rl through R~ are each independently
(i) when connected to a carbon atom:
hydrogen, C1_6 alkyl, C3_6 cycloalkyl, C1_3 allcoxy, h-butoxy, i-butoxy, sec-
butoxy, R;3R14N- (wherein R13 and R14 are each independently hydrogen or CI_3
alkyl),
tTifluoromethyl, trifluoromethoxy, difluorometho~~y, fluoro, chloro, bromo,
cyano, acetyl,
-15-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
amino, borono, nitro, carboxyl, CI_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, diphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH NOH, -C=NOHCH3, -S03H, -SOaCH3, -S02NHRls (wherein Rls is hydrogen or
CI_3 alkyl), or -O(CH2)"OR16- (wherein R16 is hydrogen or Cl_3 alkyl, and n is
1, 2 or 3);
or when any two R;s are located at the ortlzo position to each other, they
together form -
~1=~2-z3=~4- (wherein ZI through Z4 each independently represents CH or N), -S-
CO-
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O- , -
N=CH-S- or -O-CH2CH2-O-; or
(ii) when connected to a nitrogen atom;
absent;
and
X, Y and Z are each independently carbon or nitrogen.
In a preferred embodiment of the fourth embodiment,
Rl, R3 and R4 are each hydrogen;
R~ is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -S02CH3 and -SO2NH2;
Rs 15:
(i) when ~ is nitrogen:
absent, and
(ii) when X is carbon:
hydrogen, C1_q. alkyl, C3_6 cycloalkyl, Cl_3 alkoxy, trifluoromethyl, fluoro,
chloro, brow~, cyano, acetyl, amino, borono, nitro, carboxyl, Ca_~
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl, hydroxymethyl, -CHO, _
CH=i~TOH, -~"=i~TOFI~'H~s -SO~I~~ -S09CH,, -SO~~TH2, or when lay are located
at the
~rtlr.~ position to another R;, they together f~rn.~-Z1=Z2-% 3=Zq- (whereas Zr
through /~4
each indepeaidently represents CH or l~l), -S-CO-O-, -CH=CH-1~T~I-, -CH=CH-S-,
-
C>=I=CH-O-, -hT=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -~-CHZCH2-O-;
Rg 1S:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, C1_4 all~yl, C3_6 cycloallcyl, C1_3 allcoxy, trifluoromethyl,
fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, Ci_4
alkoxycarbonyl,
_1 g_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH NOH, -C=NOHCH3, -S03H, -SOZCH3, -SOZNH2, or when R6 are located at the
of~tho position to another R;, they together form -Zl=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N N-O-, -N=CH-S- or -O-CH2CHz-O-;
R7 is:
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, C1_4 alkyl, C3_~ cycloallcyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -S~2CH3, -SOzNH2, or when R7 are located at the
o~tlao position to another R;, they together form -Zl=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-~-, -N=CH-NH-, -CH2-N=N-, -N N-O-, -N=CH-S- or -O-CHzCHZ-O-;
R8 through R9 are each independently hydrogen, C1_~ alkyl, C3_6 cycloalkyl,
Cl_3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
nitro,
carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -CHO, -CH=NOH, -C=N~HCH3,-S~3H, -S~zCH3, -SOZNHZ, or when
any two R;s are located at the oy°th~ position to each other, they
together form -ZI=ZZ-
~3=Z~- (wherein ~1 through ~4 each independently represents CH or N), -S-CO-O-
, -
CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-
S- or -O-CH2CH2-O-; and
2~ ~'~, ~° as~d ~ are each independently carbon gar ~a~l:rogei~e
In one particular embodiment of the fourth embodment, the compounds
of the present invention are represented by formula. ~(1~)
wherein Rl through R9 axe each independently
(i) when connected to a carbon atone:
hydrogen, Cl_G alkyl, C3_6 cycloallcyl, C1_3 allcoxy, n-butoxy, z-butoxy, sec-
butoxy, R13R1qN- (wherein R;3 and R;4 are each independently hydrogen or C1_3
allcyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, nitro, carbo~~yl, C1_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, diphenyl-t-butylsilyloxy,
hydroxymethyl, -CH~,
-17-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
-CH=NOH, -C--NOHCH3, -S03H, -SO2CH3, -SOzNHRIS (wherein Rls is hydrogen or
C1_3 alkyl), or -O(CHz)"OR16- (wherein R16 is hydrogen or C1_3 alkyl, and n is
l, 2 or 3);
or when any two R;s are located at the oYtho position to each other, they
together form -
~1=~2-~3=~4' (wherein Zl through Z4 each independently represents CH or N), -S-
CO-
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N N-, -N N-O-, -
N=CH-S- or -O-CHzCHz-O-; or
(ii) when connected to a nitrogen atom;
absent; and
X, Y and Z are each independently carbon or nitrogen;
with the proviso that
when Rl=Rz=R3=R4=RS=R6=R8=R9 = hydrogen, and X=Y=Z=carbon; R~
is not Cl, CN, OCH3, NOz, CF3, H, or COOCH3;
when Rl=Rz=R3=R4=Rs=R7=R8=R9 = hydrogen, and X=Y=Z=carbon; R6
is not CN, NOz, or CF3;
when Rl=Rz=R3=R4=Rs=R$=Rg = hydrogen, and X=Y=Z=carbon; R6 and
R7 together is not -CH=CH-CH=CH-;
when Rl=Rz=R3=R4=Rg=R7=R8= R9=hydrogen, and X=Y=Z=carbon; RS
is not OCOCH3;
when Rl=R3=R4=Rs=R6=R7=R8= R~ = hydrogen, and X=Y=Z=carbon;
R2 is not COON; and
when Rl=Rz=R3=R~=RS=Rg= R9 = hydrogen, R6= Cl, and X=Y=Z=carbon;
R7 is not Cl.
Tn a preferred embodiment of the fourth embodiment, the compounds of
~5 the p~°e~ent iamfentiun are reps°esented by forimula A(T~)
wherein
Rl, lZ~ and R4 are each hydrogen;
Rz is hydrogen , fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carbonyl, C1_~ alko~ycarbo~ayl, pheno~ycarbonyl, hydroxyl, -CHO, -CH=1~TOH, _
C=NOHCH3, -S03H, -SOzCH3 and -SOzNHz;
Rs is:
(i) when X is nitrogen:
absent, and
(ii) when d~ is carbon:
-1 S-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen, Cl_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -S02CH3, -SOZNH2, or when RS are located at the
ortho position to another R;, they together form -Zl=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-;
R6 is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is caxbon:
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoxo,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -SOaCH3, -SOZNH2, or when R6 are located at the
o~tho position to another R;, they together form -Zl=ZZ-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCHZ-O-;
R7 is:
(i) when Z is ntrogen:
absent, and
(ii) when Z is carbon:
hydrogen, Cl_4 alkyl, C3_6 cycloalkyl, Ci_3 allcoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, CI_~
alkoxycarbonyl,
?5 laheryrl, pl~eno~cy, phem~~ycarboa2yl, l~aeaa~.ylo~~~r, layd~-~a~cyl,
h~rd2°o~~n~mtlyl~ -C'HO~ _
CH=1~TOH, -C=1\TOHCH3, -S03H, -SOZCH~, -S~2NH2, or when I~7 axe located at the
cai°tdr~ position to another R;, they together form -~1=Z~-Z3=Z4-
(~~hexein ~1 through Z~4
each independently represents CH or 1~T), -S-CO-~-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHZ-N=ICI-, -N=N-O-, -N=CH-S- or -~-CH2CH2-~-;
R8 through R~ are each independently hydrogen, C1_4 alkyl, C3_6 cycloallcyl,
CI_3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
vitro,
carboxyl, C1_4 allcoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -CHO, -CH=NOH, -C=NOHCH3,-S~3H, -S~zCH3, -SOZNHa, or when
any two R;s are located at the ortla~ position to each other, they together
form -Zl=ZZ-
-19-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Z3=Z4- (wherein ZI through Z4 each independently represents CH or N), -S-CO-O-
, -
CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-
S- or-O-CHZCHZ-O-; and
X, Y and Z are each independently carbon or nitrogen;
with the proviso that
when Rl=RZ=R3=Rq.=RS=R6=R$=R9 = hydrogen, and X=Y=Z=carbon; R~
is not Cl, CN, OCH3, NOa, CF3, H, or COOCH3;
when RI=R2=R3=R4=RS=R7=R8=R9 = hydrogen, and X=Y=Z=carbon; R6
is not CN, NOZ, or CF3;
I O when Rl=R2=R3=Rq=RS=R8=R~ = hydrogen, and X=Y=Z=carbon; R6 and
R7 together is not -CH=CH-CH=CH-;
when Rl=RZ=R3=R4.=R~=R~=R8= R9=hydrogen, and X=Y=Z=carbon; RS
is not OCOCH3;
when Rl=R3 Rq.=RS=R6=R7=R$= R9=hydrogen, and X=Y=Z=carbon; Ra
is not COON; and
when Rl=R2=R3=R4=RS=R8= R9=hydrogen, R6= Cl, and X=Y=Z=carbon;
R7 is not Cl.
In a fifth embodiment, the compounds of the present invention are
~0 represented by fonnula A(V):
R1
R
wherein RI through R9 are each independently hydrogen, C1_6 allcyl, C3_6
cycloallcyl, C1_3 alkoxy, zz-butoxy, i-butoxy, sec-butoxy, R13R14N- (wherein
R13 and Rl~
each independently represents hydrogen or CI_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, nitro, amino, borono,
carboxyl,
Ct_6 alkoxycarbonyl, phenyl, phenoa~y, phenoxycarbonyl, ben~,yloxy, hydros~yl,
-20-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SO2CH3, -
S02NHR15 (wherein RIS is hydrogen or C1_3 alkyl), or -O(CHZ)"OR16- (wherein
R16 is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the ortlao
position to each other, they together form -Zl=Z~,-Z3=Z4- (wherein Zl through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O~,
-N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCHZ-O-.
In a preferred embodiment of the fifth embodiment,
Rl and R4 are each hydrogen;
R2 and R3 are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, amino, borono, nitro, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-SO3H, -SOzCH3 and -SO2NH2;
RS through R~ are each independently hydrogen, C1~ alkyl, C3_6
cycloalkyl, Cl_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -S03H, -SO2CH3, -SOZNH2, or when any two
R;s
are located at the or~tlao position to each other, they together form -Zl=Z2-
Z3=Za-
(wherein Zl through ~4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N N-, -N--~T-O-, -IV=CH-S- or -O-
CH2CHz-O-.
In one particular embodiment of the fifth embodiment, the compounds of
the present invention are represented by formula A(V):
wherein R; through R9 are each independently hydrogen, C1_~ alkyl, C3_G
cycioallcyl, C1_3 alkoxy, ~z-butoxy, i-butoxy, sec-butoxy, RI3R14N- (wherein
R;3 and R14
each independently represents hydrogen or Ci_3 allcyl), trifluoromethyl,
trifluoromethoxy,
'~5 difluoror~mtho«y, fluoro, c111~r~, bromo, cyanca, acetyl, nitrca, amino,
boronca, c~rbo~~yl,
C1_~ alkoxycarbonyl, phenyl, phenos~y, phenoxycarbonyl, benzyloxy, hydro~~yl,
trirnethylsilylo~~y, Biphenyl-t-butylsilylo~~y, hydroxyi~~ethyl, -SO3H, -
SO~CH39 -
SOzNHRIS (wherein Ri~ is hydrogen or C1_3 alkyl), or -O(CHa)"OR16- (wherein
Rl~ is
hydrogen or C1_3 allcyl, and n is 1, 2 or 3); or when any two R;s are located
at the or~tlao
position to each other, they together form -Zl=Za-Z3=Z4- (wherein Zl through
Z~ each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, ~CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHI-IV=N-, -N=N-O-, -N=CH-S- or -O-CH2CHa-O-;
with the proviso that
-21-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
when Rl=RZ R3--R4=RS=R6=Rg=R9 = hydrogen; R7 is not H, OH ox
C(CH3)3.
In another embodiment of the fifth embodiment,
Ri and R4 are each hydrogen;
R2 and R3 are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, amino, borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-SO3H, -S02CH3 and -SOzNHz;
RS through R9 are each independently hydrogen, C1_4 allcyl, C3_6
cycloalkyl, CI_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
ZO borono, vitro, carboxyl, Cj_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -S03H, -SOzCH3, -SOzNHz, or when any two
R;s
are located at the ortlao position to each other, they together form -Zl=Zz-
Z3=Z4-
(wherein Zl through Z4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-
CHzCHz-O-;
with the proviso that
when Rl=RZ=R3=Rq=RS=Rg=Rg=R9 = hydrogen; R7 is not H, OH or
C(CH3)3.
In a sixth embodiment, the compounds of the present invention are
represented by formula A(VI):
A(VI)
ozr.~
In a seventh embodinmnt, the compounds of the present invention are
represented by formula ~(~II):
A(VII)
wherein Q is oxygen or lone-pair electrons.
-22-
N~?~ /OH
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
In an eighth embodiment, the compounds of the present invention are
represented by formula A(VIII):
He
In a ninth embodiment, the compounds of the present invention are
represented by formula A(IX):
H(
In a tenth embodiment, the compounds of the present invention are
represented by formula A(X):
N(
A(X)
Tn an eleventh embodiment, the compounds of the present invention are
re~aa-ese~~ted la;~ fo~nula ~(:~~1~:
H~~ SCaN
A(XI)
R~
wherein Rj is hydrogen, C1_6 allcyl, C3_6 cycloall~yl, C1_3 alkoxy, ri-butoxy,
i-
butoxy, sec-butoxy, R13R14N- (wherein R13 and Ri4 are each independently
hydrogen or
CI_~ all~yl), trifluorornethyl, trifluoron~etho~~y, difluorometho~~y, fluoro,
chloro, brorn~,
cyano, acetyl, amino, borono, nitro, carboxyl, C1_6 allcoxycarbonyl, phenyl,
phenoxy,
-23-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
phenoxycarbonyl, benzyloxy, hydroxyl, trimethylsilyloxy, diphenyl-t-
butylsilyloxy,
hydroxymethyl, -S03H, -S02CH3, -SOZNHRIS (wherein Rls is hydrogen or C1_3
alkyl), or
-O(CHZ)"OR16- (wherein R16 is hydrogen or C1_3 alkyl, and n is 1, 2 or 3).
In a preferred embodiment of the eleventh embodiment,
Rl is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitro,
carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -S03H, -S02CH3 and -
SO2NHa.
In one particular embodiment of the eleventh embodiment, the
compounds of the present invention are represented by formula A(XI~,
wherein Rl is C1_6 alkyl, C3_6 cycloallcyl, CI_3 alkoxy, fz-butoxy, i-butoxy,
sec-
butoxy, R13Ri4N- (wherein R13 and R14 are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOZCH3, -
SOaNHRIS (wherein Rls is hydrogen or CI_3 alkyl), or -O(CH2)"OR16- (wherein
R16 is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3).
In another embodiment of the eleventh embodiment,
RI is fluoro, chloro, bromo, cyano, acetyl, carboxyl, Cl_4 alkoxycarbonyl,
phenoxycarbonyl, hydroxyl, -S03H, -SOzCH3 and -SOaNH2.
In a twelfth embodiment, the compounds of the present invention are
represented by formula A(XII):
H~~ /oH
" " ~II)
~~6
Y
Ra
wherein R1 through R9 are each independently
(i) when connected to a carbon atom:
hydrogen, C1_6 alkyl, C3_s cycloalkyl, C1_3 alkoxy, fz-butoxy, i-butoxy, sec-
butoxy, R13R14~- (wherein R13 and R14 ire each independently hydrogen or C1_3
allcyl),
-24-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, nitro, carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -S02CH3, -SOZNHRis (wherein Rls is hydrogen or
Cl_3 alkyl), or -O(CH2)"OR16- (wherein R16 is hydrogen or C1_3 alkyl, and n is
1, 2 or 3);
or when any two R;s are located at the o~tho position to each other, they
together form -
~1=~2-~3=~4- (wherein Z; through Z4 each independently represents CH or N), -S-
CO-
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHa-N=N-, -N-N-O-, -
N=CH-S- or -O-CH2CH2-O-; or
(ii) when connected to a nitrogen atom;
absent;
and
X, Y and Z are each independently carbon or nitrogen.
In a preferred embodiment of the twelveth embodiment,
Rl, R3 and R~. are each hydrogen;
RZ is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carboxyl, Ci_4 allcoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=N~HCH3, -S~3H, -S02CH3 and -S~2NH2;
Rs 1S:
(i) when X is nitrogen:
absent, and
(ii) when X is carbon:
hydrogen, Ci_4 alkyl, C3_~ cycloallcyl, CI_3 allcoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, an Wino, borono, nitro9 carboxyl, C1_4.
alkoxycarbonyl,
phetyl, plmz~os~y q phea~c~~c;rcarbo~~yl, beaa~,ylca~~y, bydro~~yl~
hy~.ro~~~~~aaetl~~rl~ -CHO9 -
CH=NOH, -C=NOHCH3, -S03H, -S~2CH3, -S~zl~TH2, or when Rs are located at the
oy~tlzo position to another R;, they together form -Z1=Z~-G3=Z4- (wherein Z;
thr~ugh Z~
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CH~CHZ-O-;
R~ is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
-25-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen, C1_4 alkyl, C~_6 cycloalkyl, C;_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, Cr_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -SO2CH3, -SO2NH2, or when R6 are located at the
o~tho position to another R;, they together form -Z1=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHa-N=N-, -N N-O-, -N=CH-S- or -O-CH2CH2-O-;
R7 is:
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, C1_~ alkyl, C3_6 cycloalkyl, C1_3 all~oxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amin~, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH NOH, -C=NOHCH3, -S03H, -S02CH3, -SOzNH2, or when R7 are located at the
or~tho position to another R;, they together forni -Z;=Zz-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
' - -9 - ' - '' - 2- -~ - _ - -9 - ' H-S- ~r -~-C Z
R8 through R9 are each independently hydrogen, C1_q. alkyl, C3_6 cycloalkyl,
C1_3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyan~, acetyl, amino, borono,
vitro,
carboxyl, C;_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -CHO, -CH=NOH, -C=NOHCH3, -S~3H, -SOaCH3, -S02NH2, or when
any two R;s are located at the ~~t'la~ position to each other, they together
form -Zl=Zz-
Zs=Za- (wherein Zl through Z4 each independently represents CH or N), -S-CO-O-
, -
CH=CH-1~T~I-, -~':H=~'H_S-, _~°I~=CH-O_, -I!T=C'H-1~TH-, -~'H~-~T=i~I-,
-~T=1'~l-O-, -l~T=CH-
S- or -~-CH2CH2-~-~ and
~~, ~ and Z are each independently carbon or nitr~gene
In a thirteenth embodiment, the compounds of the present invention are
represented by formula A(~III):
-26-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
A(XIII)
wherein RI through RIZ are each independently hydrogen, C1_6 alkyl, C3_6
cycloalkyl, Ci_3 alkoxy, n-butoxy, i-butoxy, sec-butoxy, RI3Ri4N- (wherein R13
and RI4
are each independently hydrogen or C1_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
C1-6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOZCH3, -
SO2NHR15 (wherein RIS is hydrogen or Cl_3 alkyl), or -O(CHa)"ORt6- (wherein
R16 is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the o~tho
position to each other, they together form -~I=~2-Z3=~4- (wherein Z; through
Z~ each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CH2-N=N-, -N N-~-, -N=CH-S- or -O-CI3zCH~-O-.
In a preferred embodiment of the thil-teenth embodiment,
Rl, R3, R4, R9, Rl l and R12 are each hydrogen;
RZ and RIO are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, vitro, amino, borono, carboxyl, CI-~ alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-S03H, -~02CH3 and -SOaNH2;
RS through R$ are each independently hydrogen, C1_4 alkyl, C3_6
cycloallcyl, C1_3 alkoxy, trifluoromethyl, flL2oro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, CI_~ alk~xycarbon yl, phenyl, pheno~~y,
phenoxycarbonyla
bera~,yloxy, hydro~~yl, hydroa~ymethyl, -~O3H, -SOZCH3, -SO~~THI2, or when any
te~ro R;s
am located at the ~y~tln~ position to each other, they together form -/21=~z-%
s=~a-
(wherein ~i through ~~ eaeh independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N N-O-, -N=CH-S- or -~-
CHaCH2-O-.
In a fourteenth embodiment, the compounds of the present invention are
represented by formula A(~I~):
-27-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
wherein Rl through R9 are each independently hydrogen, C1_s alkyl, C3_s
cycloalkyl, C1_3 allcoxy, n-butoxy, i-butoxy, sec-butoxy, R13R14N- (wherein
R13 and Rla
each independently represents hydrogen or C1_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, vitro, amino, borono,
carboxyl,
Cl_s alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SOZCH3, -
SOZNHRIS (wherein Rls is hydrogen or C1_3 alkyl), or -O(CH2)"ORIS- (wherein
Ris is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the ~rth~
position to each other, they together form -Zi=Z2-Z3=~4- (wherein 201 through
Z~ each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N-N-O-, -N=CH-S- or -O-CH2CH2-O-.
W a preferred embodiment of the fourteenth embodiment,
Rt and R~ are each hydrogen;
RZ and R3 are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, amino, borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-SO3H, -SO2CH3 and -SOZNH2;
h~s through R~ are each independently hyda-ogen9 C;_~ alkyl, C'~_s
cycloallcyl, C1_3 allcoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
ben~,yloxy, hydro~~yl, hydroxymethyl, -SO3H, -SOZC'H~, -SOzI~~II2, or when any
tyro R;s
are located at the of~th~ position to each other, they together form -~1=~z-
~3=~a-
(wherein Zl through ~4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-
CHZCHZ-O-.
Tn a fifteenth embodiment, the compounds of the present invention are
represented by formula ~1(~V):
-28-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
wherein Rl through Riz are each independently hydrogen, C1_s alkyl, C3_s
cycloalkyl, C1_3 alkoxy, ya-butoxy, i-butoxy, sec-butoxy, Rl3RiaN- (wherein
RI3 and R14
are each independently hydrogen or C1_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
C1_s alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -S02CH3, -
SOzNHRIS (wherein Rls is hydrogen or C1_3 alkyl), or -O(CHz)"ORIS- (wherein
Rls is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the ~~tho
position to each other, they together form -Zl=Z2-~3=Z~- (wherein Zl through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -~-CHzCHz-~-.
In a preferred embodiment of the fifteenth embodiment,
R1, R3, R4, R9, RI1 and Rlz are each hydrogen;
Rz and Rlo are each independently hydrogen, fluoro, ehloro, bromo, cyano,
acetyl, vitro, amino, borono, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-S03H, -SOzCH3 and -SOzNHz;
Rs through R$ are each independently hydrogen, C1_q. allcyl, C3_6
~:~rcloall<yl, C1_~ ~lkoify~ triflt~~orometh~rl~ f~uoro9 chloro, ba-om~a
cyano~ acet~rl, a~a~ino,
borono, vitro, carboxyl, C1_~ alkoxycarbonyl, phenyl, phenoay,
pheno~~ycarbonyl,
ben~yloxy, hydr~~cyl, hydro~~ymethyl, -SO3H, -SOzCH3, -SOzI~THz, or when any
two R;s
are located at the eay~tla~ position to each other, they together form -~GI=Gz-
~~=~4-
(wherein ~1 through ~4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N N-, -N=N-O-, -N=CH-S- or -O-
CHZCHz-O-.
In certain embodiments, the invention is directed to compounds
represented by formula ~(XVI~:
-29-
HO~ ,OH HO~ /OH
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
n(xm)
wherein Rl through R12 are each independently hydrogen, C1_6 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, zz-butoxy, i-butoxy, sec-butoxy, R13R1~N- (wherein
R13 and R14
are each independently hydrogen or Cl_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitro,
carboxyl,
Cl_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOaCH3, -
S02NHR15 (wherein Rls is hydrogen or C1_3 alkyl), or -O(CH2)"OR16- (wherein
R16 is
hydrogen or C1_3 alkyl, and n is l, 2 or 3); or when any two R;s are located
at the ortho
position to each other, they together form -~1=Z2-Z3°~4- (v~'herein Zl
through Z4. each
independently represents CH or N), -S-C~-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-~-,
-N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-.
In certain preferred embodiments of the invention is directed to
compounds represents by formula A(~VI) wherein ,
Rl, R3, R4, R9, Rli and R12 ass each hydrogen;
R~ and Rlo are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl,
vitro, amino, borono, carboxyl, Cl_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl, -S03H,
-~'OyC~T~ and -SO~t~IIT~;
R5 through R$ are each independently hydrogen, CI_4 alkyl, C~_~ cycloalkyl,
Cj_3
alkos~y, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
vitro,
carbonyl, C1_4 all~o~~ycarbonyl, phenyl, phenoxy, plaenoxycarbonyl, ben~ylo~y,
hydro~~yl,
hydroxymethyl, -S03H, -SO2CH3, -SOaNH2, or when any two R;s am located at the
~~~lz~
position to each other, they together form -~I=~2-Z3°~4- (wherein Zl
through Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHa-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-.
In certain embodiments, the invention is directed to compounds
represented by formula A(~~II):
-3 0-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
A(XVII)
HO~ OOH
wherein RI through R;z are each independently hydrogen, CI_6 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, n-butoxy, i-butoxy, sec-butoxy, RI3RI4N- (wherein RI3
and RI4
are each independently hydrogen or CI_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitro,
carboxyl,
CI_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trin-Iethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOzCH3, -
SOzNHRIS (wherein RIS is hydrogen or CI_3 alkyl), or -O(CHz)"ORI6- (wherein
RI6 is
hydrogen or CI_3 alkyl, and n is I, 2 or 3); or when any two R;s are located
at the o~tla~
position to each other, they together form -~I=~z-~s=~4- (wherein ~I through
~~ each
independently represents CH or N), -S-CO-~-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-~-,
-N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCHz-O-.
In entain prefm-red embodiments the invention is directed to compounds
represented by formula h(~VII) wherein,
R;, R3, R4, R9, RII and RIZ are each hydrogen;
Rz and Rio are each independently hydrogen, fluoro, chlor~, bromo, cyano,
acetyl,
vitro, amino, borono, earbo;~yl, CI_q. alkoxycarbonyl, phenoxycarbonyl,
hydroxyl, -SO3H,
-S' Oz ~.'H3 and -50z1'~ZHz;
R~ through R$ are each independently hydrogen, CI_4 allcyl, C3_~ cycloalleyl,
C1_3
alko~y, trifluoromethyl, ~u~ro, chloro, brorno, cyaaa~, acetyl, amino,
boronoa, vitro,
carboxyl, CI_q. alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, ben~yloxy,
hydro~~yl,
hydroxyrnethyl, -S03H, -SOzCH3, -SOzNHz, or when any two R;s are located at
the ~rtho
position to each other, they together form -ZI=~2-.~3°~4- (wherein ZI
through Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCHz-O-.
-31-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
In a certain embodiments, the invention is directed to compounds
represented by formula A(XVIII):
A(XVIII)
a
wherein RI through RZo are each independently hydrogen, CI_6 alkyl, C3_6
cycloalkyl, CI_3 alkoxy, ya-butoxy, i-butoxy, sec-butoxy, RI3RI4N- (wherein
RI3 and RIB
are each independently hydrogen or CL3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
CI_G alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SOZCH3a -
SOZIVHRIg (wherein RIS is hydrogen or CI_3 alkyl), or -~(CH~,)nORIG- (wherein
RIG is
hydrogen or CI_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the of~tho
position to each other, they together form -~I=~,~-~3=~4- (wherein ~I through
~4 each
independently represents CH or N), -s-CO-O-, -CH=CH-IVH-, -CH=CH-S-, -CH=CH-O-
,
-N=CH-IVH-, -CH2-N=I~T-, -N=IV-~-, -1V=CH-S- Or -~-CH2CH2-~-.
1~ In ertairl prefel-~-ed el~bodinaents the in~rention as dixected tea
coa~~Ipoa~nds
represented by formula I~(~.~III) wherein,
RI, R3, R~, R~, RIIa Ru~ Rl7a RI9 and Rio are each lsydrogen;
R~, RIO and RI$ are each independently hydrogen, fluoro, chloro, bromo,
cyaxlo,
acetyl, vitro, amino, borono, carboxyl, CI_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-S03H, -SOZCH3 and -SOaNH2;
RS through R7 are each independently hydrogen, CI_~ alkyl, C3_G cycloallcyl,
CI-3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
vitro,
carbo~~yl, CI_~ alkoxycarbonyl, phenyl, phenoxy, phenoxycsrbonyl, bemyloxy,
hydroxyl,
hydroxymethyl, -SO3H, -SOzCH3, -SO2NH2.
-32-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
The invention relates to a method of inhibiting ~3-lactamase comprising
contacting the ~i-lactamase with an effective amount of one or more compounds
of
formula A(I), A(II), A(III), A(IV), A(V), A(VI), A(VII), A(VIII), A(IX), A(X),
A(XI),
A(XII), A(XIII), A(XIV), A(XV), A(XVI), A(XVII) or A(XVIII).
The invention provides a method of treating bacterial infection,
particularly (3-lactam-antibiotic-resistant bacterial infection. The method
comprises
administering to a subject suffering from such an infection an effective
amount of one or
more compounds of formula A(I), A(II), A(III), A(IV), A(V), A(VI), A(VII),
A(VIII),
A(IX), A(X), A(XI), A(XII), A(XIII), A(XIV), A(XV), A(XVI), A(XVII), or
A(XVIII).
The invention also provides a method of treating bacterial infection,
particularly,~-lactam-antibiotic-resistant bacterial infection. The method
comprises
administering a subj ect suffering from such an infection an effective amount
of one or
more compounds of formula A(I), A(II~, A(III), A(IV), A(V), A(VI), A(VII),
A(VIII),
A(IX), A(X), A(XI), A(XII), A(XIII), A(XIV), A(XV), A(XVI), A(XVII), or
A(XVIII);
and an effective amount of ,~-lactam-antibiotic, with or without one or more
other
antibacterial agent.
The invention further provides a method of overcoming bacterial
resistances, particularly resistance to ~'-lactam-antibiotic. The method
comprises
administering a subject an effective amount of one or more compounds of
formula A(I),
A(II), A(III), A(IV), A(V), A(VI), A(VII), A(VIII), A(IX), A(X), A(XI),
A(XII),
A(XIII), A(XIV), A(XV), A(XVI), A(XVII), or A(XVIII); and an effective amount
of ~3-
lactam-antibiotic, with or without one or more other antibacterial agent.
The invention also provides a pharmaceutical composition comprising
one or more compounds of formula A(I), A(II), A(III), A(IV), A(V), A(VI),
A(VII),
~.(~%III), ~(I~~j, ~(~'~), ~(aT>I), f~(>~II)a ~(a~III), ~(~~I-~~")a ~(ar~~C),
~(sVI), ~(d'~~iII)~ or
A(XVIII) and a pharmaceutically acceptable carrier.
The invention further provides a pharmaceutical composition comprising
one or more compounds of fornmla A(Ij, A(II), A(III), A(IV), A(V), A(VI),
A(VII),
A(VIII), A(IX), A(X), A(XI), A(XII), A(XIII), A(XIV), A(XV), A(XVI), A(XVII),
or
A(XVIII); a,~-lactam-antibiotic, and optionally comprising one or more other
antibacterial agent; and a pharmaceutically acceptable carrier.
~'I'AII~EESCIZIPT'I1~
Tlae present invention provides compounds having the formula:
-33-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(1-IO)a_B_T (A)
wherein B stands for boron, and
T has one of the following structures:
/Rs (I)
\R7
Hfl'~ OOH
0
(II)
a
Re
R Ra
7
(lli)
RB Ry
..~ ~ Rs
a
R~
R2
Q~ ~Q (Vfl)
,s,
P _
-34-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(IX)
(VIII)
y NJ
(X)
o _ ~ ~ ~ , 0,
/Rs
(XII)
Z
(XIV)
a and
H~~ OOH
ca
(XV)
wherein Iy through Riz are each independently
-35-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(i) when connected to a carbon atom:
hydrogen, C1_6 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, fZ-butoxy, i-butoxy, sec-
butoxy, Rl3RiaN- (wherein R13 and R14 are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, nitro, carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -S~2CH3, -SOzNHRIS (wherein Rls is hydrogen or
C1_3 alkyl), or -O(CH2)"OR16- (wherein R16 is hydrogen or C1_3 alkyl, and n is
1, 2 or 3);
or when any two R;s are located at the o~tJz.o position to each other, they
together form -
1 O Zl=ZZ-Z3=Z4- (wherein Zl through Z4 each independently represents CH or
N), -S-CO-
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N N-O-, -
N=CH-S- or -O-CH2CH2-O-;
or
(ii) when connected to a nitrogen atom:
absent;
and
X, ~' and Z are each independently carbon or nitrogen.
The compounds of the present invention are specifically described by
formula A(I), A(II), A(III), A(TV), A(V), A(VI), A(VII), A(VIII), A(IX), A(~),
A(XI),
A(~II), A(XIII), A(~I~), A(~~), A(X~I), A(~VII) and/or A(X~III) below.
The invention relates to a method of inhibiting (3-lactamase comprising
contacting the ,~-lactamase with an effective amount of one or more compounds
of
formula A(I), A(II), A(III), A(I~), A(V), A(~I), A(~II), A(VIII), A(I~), A(~),
A(XI),
A(~II), A(~III), A(~I~), A(XV), A(X~I), A(XVII) or A(~~III).
The invention px~a~ides a ~a~etho~l of treating baci:erial infection
particularly ,~-lactam-antibiotic-resistant bacterial infection. The method
comprises
administering to a subject suffering from such an infection an effective
amount of one or
more compounds of formula A(1', A(II), A(III), A(I5j), A(~), A(VT), A('~IT),
A(SIIII),
A(I~), A(X), A(~I), A(XII), A(XIII), A(XI~), A(~V), A(~~I), A(~V'TI) or
A(X~TIII).
The invention also provides a method of treating bacterial infection,
particularly (3-lactam-antibiotic-resistant bacterial infection. The method
comprises
administering a subject suffering from such an infection an effective amount
of one or
more compounds of formula A(I), A(II), A(III), A(IV), A(~), A(~I), A(VIT),
A(VIII),
-3 6-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
A(IX), A(X), A(XI), A(XII), A(XIII), A(XIV), A(XV), A(XVI), A(XVII) or
A(XVIII);
and an effective amount of ,Q-Iactam-antibiotic.
The invention further provides a method of overcoming bacterial
resistances, particularly resistance to ~3-lactam-antibiotic. The method
comprises
adminstering a subject an effective amount of one or more compounds of formula
A(I),
A(II), A(III), A(IV), A(V), A(VI), A(VII), A(VIII), A(IX), A(X), A(XI),
A(XII),
A(XIII), A(XIV), A(XV), A(XVI), A(XVII) or A(XVIII); and an effective amount
of (3-
lactam-antibiotic or other antibacterial agent.
The invention also provides a pharmaceutical composition comprising
one or more compounds of formula A(I), A(II), A(III), A(IV), A(V), A(VI),
A(VII),
A(VIII), A(IX), A(X), A(XI), A(XII), A(XIII), A(XIV), A(XV), A(XVT), A(XVII)
or
A(XVIII); and a pharmaceutically acceptable carrier.
The invention further provides a pharmaceutical composition comprising
one or more compounds of formula A(I), A(II), A(III), A(1V), A(V), A(VI),
A(VII),
A(VIII), A(IX), A(X), A(XI), A(XII), A(XIII), A(XTV), A(XV), A(XVT), A(XVTI)
or
A(XVIII); a ~3-lactam-antibiotic or other antibacterial agent; and a
pharmaceutically
acceptable carrier.
Formula A(Il
In a first embodiment, the compounds of the present invention are
represented by formula A(I):
/RG ~
Y
R~
wherein R1 through R~ are each independently
(i) when connected to a carbon atom:
hydrogen, C1_6 allcyl, C3_6 cycloallcyl, C1_3 allcoxy, fa-butoxy, i-butoxy,
sec-
butoxy, R1~R~41~T- (wherein R13 and R14 are each independently hydrogen of
C1_~ alkyl),
-37-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
trifluoromethyl, trifluorolnethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, vitro, carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -SOZCH3, -SOzNHRIS (wherein R15 is hydrogen or
C1_3 alkyl), or -O(CHz)"ORl6- (wherein RI6 is hydrogen or Cl_3 alkyl, and n is
1, 2 or 3);
or when any two R;s axe located at the oy~tlao position to each other, they
together form -
Z~=Zz-Z3=Z4- (wherein Zl through Z4 each independently represents CH or N), -S-
CO-
O-, -CH=CH-NH-, -CH=CH-S-, -CH=GH-O-, -N=CH-NH-, -CHz-N=N-, -N N-O-, -
N=CH-S- or -O-CHzCHz-O-; or
(ii) when connected to a nitrogen atom;
absent;
and
X, Y and Z axe each independently carbon or nitrogen.
In a preferred embodiment of the first embodiment,
Rl, R3 and R4 are each hydrogen;
Rz is hydrogen, fluoro, chloro, brorno, cyano, acetyl, amino, vitro,
carboxyl, Ci_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -SOzCH3 and -SOzNHz;
RS is:
(i) when X is nitrogen:
absent, and
(ii) when ~ is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloallcyl, Cl_3 allcoxy, trifluorolnethyl,
fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carbo~~yl, C1_q.
alkoxycarbonyl,
~5 phenyh plml~~a,~~r, phen oi~ycar~a~anyl, bega~ylo~~y~ 11C~ dro~~rl~
hy~lxo~y~amethyl~ -~'~I~, _
CH=1~TOH, -C=NOHCH~, -SO~H, -SOzCH3, -SOzNHz, or when R5 are located at the
~a°t~a~ position to .another R;9 they together form ~1=Zz-Z3=Z4-
(wherein Zl thuoa.~gh Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCHz-O-;
R~ 15:
(i) when Y is nitrogen:
absent, slid
(ii) when Y is carbon:
-38-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -SO3H, -S02CH3, -SOzNHz, or when R6 are located at the
o~th~ position to another R;, they together form -Zl=Zz-Z3°Z4- (wherein
Zl through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CHz-O-;
R7 is:
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, Ci_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S~3H, -SO2CH3, -S~zNHz, or when R7 are located at the
o~tho position to another R;, they together form -Z1=Zz-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -~-CHzCHz-O-;
Rg through R9 are each independently hydrogen, C1_4 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -CHO, -CH=N~H, -C=NOHCH3, -S03H, -
SOzCH3, -SOzNHz, or when any two R;s are located at the ~~th~ position to each
other,
they together form -Zl=Zz-Z3=Z4- (wherein ZI through Z~ each independently
represents
~5 CH ~r 1 ~~, -~-CO-~-, -CH=~'I-T-i~~I-, -~'H=~.'~T_~'-~ -I~'H=~'H-~-, -
~T=tCH-i'~~I-9 -C~Ta-
N=~T-, -I~T=N-~-, -N=CH-S- or -O-CHzCHz-O-; and
~~, ~7 and Z are each independently carbon or nitrogen.
Non-limiting specific compounds descuibed by fonn~ula ~(I) are listed in
Table 1.
Table 1: Representative Comp~unds in F~rmula A(I):
~1 RZ ~3 ~ ~5 Rl R7 ~g 129 x
H N~z H H H H ~~Z H H C C C
H N~2 H H NC~~ H H H H C C C
-39-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
H NOZ H H H NOz H H H C C C
H NOZ H H H H OCH3 H H C C C
H NOz H H H H COOCHZCH H H C C C
3
H NOZ H H H [1,3]oxathiol-2-one H H C C C
H NOZ H H CN H H H H C C C
H NOZ H H Cl H H H NOZ C C C
H NOz H H COOCHZCH3 H H H H C C C
H NOZ H H Cl H H H H C C C
H NOz H H CH3 H H H H C C C
H NOz H H OCH3 H H H H C C C
H NOZ H H H CH3 H H H C C C
H NOZ H H Cl H H H Cl C C C
H NOZ H H F H H H H C C C
H NOZ H H F H H H F C C C
H NOZ H H H H F H H C C C
H NOZ H H H H - - H H C C N
H NOz H H Cl - - H H H C N C
H NOZ H H H H H H H C C C
H NOZ H H Br H H H H C C C
H NOZ H H H B(OH)ZH H H C C C
H NOZ H H Cl H Cl H NOZ C C C
H COON H H Cl H H H Cl C C C
H NOZ H H COCH3 H H H H C C C
H NO~ H H H -CH=CH-CH=CH- H H C C C
H NOZ H H H H COON H H C C C
H NOZ H H OH H H H H C C C
H NOZ H H NHz H H H H C C C
1-T_PTO-~ H 1-I ~'HO 1-1 hI ~I H ~' C C
H NOZ H H CH=NOH H H H H C C C
H NOZ H H C=NOHCH3 H H H H C C C
H H NOz H Cl H H H Cl C C C
H H C1 H C1 H H H C1 C C C
H H H H C1 H H H C1 C C C
H NOZ H H 2~4-~ichloro-H H C1 H C C C
phenoxyl
H NOZ H H Cl H Cl H Cl C C C
~"~raa~a~la A(~~)
-40-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
In a second embodiment, the compounds of the present invention are
represented by formula A(II):
R,o
R"
A(II)
wherein R1 through R12 are each independently hydrogen, C1_6 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, n-butoxy, i-butoxy, sec-butoxy, RI3RI4N- (wherein R13
and RIa
are each independently hydrogen or C1_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
C1_~ alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SO2CH3, -
S02NHRls (wherein Rls is hydrogen or C1_3 alkyl), or -O(CH2)"ORI6- (wherein
RI6 is
hydrogen or CI_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the ~f~t72~
position to each other, they together form -~I=~2'~3°~4' (wherein ~I
through Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHa-N=N-, -N=N-O-, -N=CH-S- or -O-CHaCH2-O-.
In a preferred embodiment of the second embodiment,
RI, R3, R4, R9, RII and RIZ are each hydrogen;
I:~ and I~IU are each il~~lUpeodF~~~tly lzydrogelx, flz~~axo, chlQro, hr~tno,
cy~~~ao, acetyl,
vitro, amino, borono, carboxyl, Cl_~ alkoxycarbonyl, phenoxycarbonyl,
hydroxyl, -~03H,
-~O~CH3 and -SO~~TH~;
R5 through R$ are each independently hydrogen, C1_~. alkyl, C~_~ cycloalkyl,
C1_3
alkoxy, trifluoromethyl, fluoro, chloro, br~m~, cyano, acetyl, amino, borono,
vitro,
carboxyl, C1_4 allcoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxylnethyl, -S03H, -SOZCH3, -SOZNHa, or when any two R;s are located at
the ortho
position to each other, they together form -ZI=Z2-Z3'~4' (wherein ~1 through
~4 each
independently represents CH ~r N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCH2-O-.
-41-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Non-limiting specific compounds described by formula A(In are listed in
Table 2.
Table Z: Representative Compounds in Formula A(II):
Rl RZ R3 Ra RS Rs R~ .Rs R9 Rio Rm Ria
H NO2 H H H H H H H NOZ H H
H NOZ H H Cl H H H H NOZ H H
H H NOZ H Cl H H H NOZ H H H
H H H H Cl H H H H H H H
H NOz H H Cl Cl Cl Cl H NOZ H H
H NOZ H H t-butylH H H H N~Z H H
Formula A(III)
111 a third embodiment, the compounds of the present invention are
represented by formula A(III):
HO~B/OH Ra
R.~ ~ Ra Rs ~ ~ R7
~1(III)
Ra ~ X~ W Rs
II
R3 R
wherein 1~; through lZ9 are each independently
(i) when connected to a carbon atom:
hydrogen, CI_6 all~yl, C3_6 cycloall~yl, C1_3 all~oa~y, n-butoxy, a-butoxy,
sec-
butoa~y, I~..13I~~.l~hT- (°~rherein P I3 and I~.;~ am each
indelaendently hydrogen or ~ 1_3 allyyl)a
trifluoromethyl, trifluorometho~y, difluoron~etho~~y, fluoro, chloro, bromo,
cyano, acetyl,
IS amino, borono, nitro, carbonyl, Cl_6 alko~~ycarbonyl, phenyl, pheno~y,
plmno~~ycarbonyl,
ben~ylo~gy, hydro~~yl, trimethylsilylo~y, Biphenyl-t-butylsilylo~~y,
hydro~~ymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -SO2CH3, -S02NHRls (wherein Rls is hydrogen or
C1_3 allcyl), or -O(CH2)"~I~1G' (wherein 116 is hydrogen or C1_3 allcyl, and n
is 1, 2 or 3);
or when any two R;s are located at the os~th~ position to each other, they
together form -
~l=~2-~3' ~4- (wherein Zl through Z4 each independently represents CH or N), -
S-CO-
-42-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N N-, -N=N-O-, -
N=CH-S- or -O-CHZCH2-O-; ox
(ii) when connected to a nitrogen atom;
absent;
and
X, Y and Z are each independently carbon or nitrogen.
In a preferred embodiment of the third embodiment,
Rl, R3 and R4 are each hydrogen;
Ra is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carboxyl, Cl_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -S02CH3 and -SOZNHz;
RS is:
(i) when X is nitrogen:
absent, and
(ii) when X is carbon:
hydrogen, C1.4 alkyl, C3_6 cycloalkyl, CI_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, Cl_4
allcoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -SO3H, -SOZCH3, -SOZNH2, or when RS are located at the
~r~tla~ position to another R;, they together form -~1=Z2-~3°~4-
(wherein ~i through ~4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -~-CH2CH2-~-;
RG 1S:
(i) when Y is nitrogen:
~5 absent, atad
(ii) when ~f is carbon:
hydrogen, C1_4. alkyl, C~_6 cycloalkyl, C1_~ ~lko~~y, trifluorometllyl,
fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboa~yl, Ci_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S~3H, -S02CH3, -S02NHa, or when R6 are located at the
ortho position to another R;, they together form -.~1=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N IV-O-, -N=CH-S- or -O-CH~CHZ-O-;
R7 is:
-43-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, Cl_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxyrnethyl, -CHO, -
CH NOH, -C=NOHCH3, -S03H, -SOzCH3, -SOzNHz, or when R7 are located at the
oYtho position to another R;, they together form -Z1=Zz-Z3=Z4' (wherein ~1
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
20 CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCHz-O-;
R8 through R9 are each independently hydrogen, C1_4 alkyl, C3_s
cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, Cr_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
ben~yloxy, hydroxyl, hydroxymethyl, ~-CHO, -CH NOH, -C=NOHCH3,-S03H, -S~zCH3,
15 -SOzNHz, or when any two Rls are located at the o~tlao position to each
other, they
together form -Zl=Zz-Z3=Z4- (wherein ~1 through Z4 each independently
represents CH
or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, _
N=N-O-, -N=CH-S- or -~-CHzCHz-~-; and
~, Y and ~ are each independently carbon or nitrogen.
20 In one particular embodiment of the third embodiment, the present
invention relates to compounds represented by formula A(III)
wherein R1 through R9 are each independently
(i) when connected to a carbon atom:
hydrogen, C1_G allcyl, C3_6 cycloalkyl, C1_3 alkoxy, ya-butoxy, i-butoxy, se~-
2~ but~a~~y 1 I~I~I~ u~F- (vrhereil I~~I~ amd I~-'~Ia are ea~.h
ia~~lepmade~xtly hyd~ogei~ gar CI_~ ~llt~fl)~
trifluoromethyl, trifluoronxethoxy, difluorometho~~y, fluoro, chloro, br~111~,
cyano, acetyl,
amino, borono, vitro, carboxylP C1_~ all~oxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
ben~yloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -SOzCH3, -SOzNHRIS (wherein Rls is hydrogen or
30 C1_3 alkyl), or -O(CHz)"OR16- (wherein 81615 hydrogen or C1_3 alkyl, and n
is 1, 2 or 3);
or when any two R;s are located at the ~r~tho position to each other, they
together form -
~1=~z-~3=~4- (wherein Zl through Z4 each independently represents CH or N), -S-
CO-
_ ' -9 - - - _' - _ - -' _ ,_ - -~ - 7- - -~ - - -
N=CH-S- or -O-CHzCHz-O-; or
-44-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(ii) when connected to a nitrogen atom:
absent;
and
X, Y and Z are each independently carbon or nitrogen;
with the proviso that
when Rz=R3=R4=RS=Rb=R7=R8=R9=hydrogen, and X=Y=Z=carbon; R2
is not NH2, NOa,, or H.
In another embodiment of the third embodiment, the invention relates to
compounds described by formula A(III) wherein
Rl, R3 and R4 are each hydrogen;
RZ is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, vitro,
carboxyl, CI_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -
C=NOHCH3, -S03H, -SOZCH3 and -SO2NH2;
RS 1S:
(i) when X is nitrogen:
absent, and
(ii) when ~ is carbon:
hydrogen, C1.~ alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxcycarbonyl, ben~yloxy, hydroxyl, hydroxymethyl, -CHO, _
CH=NOH, -C=NOHCH3, -S03H, -SO2CH3, -SOZNHZ, or when RS are located at the
~y~tho position to another R;, they together form -Zl=Z2-Z3=Z~- (wherein ZI
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-,
CH=CH-O-, -N=CH-NH-, -CH2-N IV-, -N=N-O-, -N=CH-S- or -O-CH2CHZ-O-;
2S I:~i:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, Cl_4 alkyl, C3_G cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
allcoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymathyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -S~ZCH3, -S02NHz, or when Rg are located at the
~at~tda~ position to another R;, they together form -Z1=Z~-Z3=Z4- (wherein Z;
through Z4
-45-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-,
CH=CH-O-, -N=CH-NH-, -CHZ-N--N-, -N N-O-, -N=CH-S- or -O-CHZCH2-O-;
R7 is:
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloallcyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -SOzCH3, -SOZNHz, or when R7 are located at the
o~tho position to another R;, they together form -Zl=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHZ-N N-, -N=N-O-, -N=CH-S- or -O-CHZCHa-O-;
R8 through R9 are each independently hydrogen, C1_4 alkyl, C3_s
cycloallcyl, C1_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, nitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -CHO, -CH=NOH, -C=N~HCH3,-S~3H, -S~zCH3,
-S~2~2, or when any two R;s are located at the ortlao position to each other,
they
together form -Zl=ZZ-Z3=Z~- (wherein Zl through Z4 each independently
represents CH
or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N=N-, _
N=N-O-, -N=CH-S- or -O-CHZCHZ-O-; and
~, ~' and Z are each independently carbon or nitrogen;
with the proviso that
when Rl= R3= R4= RS= R6= R7= R8= R9=hydrogen, and ~=Y=Z=carbon;
R~ is not 1 ~I?,1~T~~,, or Ho
Non-limiting specific compounds described by formula (III) are listed in
'fable 3a
Table 3: Representative Compounds in Formula A(III):
Rl RZ R3 R4 RS R6 R7 Rg R9
H H H H H H H H H C C C
H NOD H H H ~I H H H C C C
-
-46-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
H N02 H H Cl H H H Cl C C C
H NO2 H H H NO2 H H H C C C
H NOZ H H H Cl H H H C C C
H NOZ H H H B(OH)Z H H H C C C
H N02 H H H COCH3 H H H C C C
H NOa H H H OH H H H C C C
H NOZ H H H COOH H H H C C C
H H H H H Cl H H H C C C
H N02 H H -CH=CH-CH=CH- H H H C C C
H NHa H H H B(OH)2 H H H C C C
H OH H H H B(OH)2 H H H C C C
In a particular preferred embodiment, the compound is
HO~B~OH
Il
O
HO~~.OH
O \
II
The compound ~ (compound F'1041) is available
from Combi-Bloclcs, Inc. (San Diego, California, Cat. No. BB-2118).
HO~,~~ OH
O
~~H
The comp~und ~ (compound F1~01) is also
available from Combi-Blocks, Inc. (San Diego, California, Cat. No. BB-2188).
F~rmula A(IV)
In a fourth embodiment, the compounds of the present invention are
represented by formula A(IV):
-47-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
R
R
Ra
A(IV)
Ra
R~
wherein R1 through R9 are each independently
(i) when connected to a carbon atom:
hydrogen, C1_6 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, ra-butoxy, i-butoxy, sec-
butoxy, R13R1aN- (wherein 813 and 814 are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, vitro, carboxyl, CI_6 allcoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, diphenyl-t-butylsilyloxy,
hydroxymethyl, -CH~,
-CH=NOH, -C-NOHCH3, -S03H, -SOZCH3, -SOZNHR15 (wherein 815 is hydrogen or
C1_3 alkyl), or -O(CH2)"~816- (wherein 81615 hydrogen or C1_3 alkyl, and n is
l, 2 or 3);
or when any two R ;s are located at the ~a~tda~ position to each other, they
together form -
~1=~2'~3=~4- (wherein ~1 through ~4 each independently represents CH or N), -S-
CO-
~-, -CH=CI-i-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=IV-O-, _
N=CH-S- or -~-CH~CH2-~-; or
(ii) when connected to a nitrogen atom;
absent;
and
a~, ~~ ald ~ are each in~lepel~~l~ntly carboy oz l~iti~gerlo
In a prefel-red embodiment of the fourth embodiment,
Rl, I2~ and Ra are each bydrogen;
RZ is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, vitro,
carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=N~H, -
C=NOHCH3, -S03H, -SOaCH3 and -SOaNH2;
RS is:
(i) when X is nitrogen:
absent, alad
(ii) when ~ is carbon:
-48-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen, Cl_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, Ct_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH--NOH, -C=NOHCH3, -S03H, -S02CH3, -S~2NH2, or when R5 are located at the
ortlao position to another R;, they together form -Zl=Z2-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-,
CH=CH-O-, -N=CH-NH-, -CHZ-N N-, -N N-O-, -N=CH-S- or -O-CHZCH2-O-;
R6 is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, C1_4 alkyl, C3_g cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxyrnethyl, -CHO, -
CH--N~H, -C=NOHCH3, -S03H, -S02CH3, -S02NHz, or when R6 are located at the
of°th~ position to another R;, they together form -Z1=Z2-Z3=Z4-
(wherein Zl through Z4.
each independently represents CH or N), -S-CO-~-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -~-CHZCHZ-~-;
R71S:
(i) when Z is nitrogen:
absent, and
(ii) when Z is carbon:
hydrogen, CI_4 allcyl, C3_6 cycloallcyl, C1_3 alkoxy, trlfluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carboxyl, C1_4
alkoxycarbonyl,
'~S phenyl, phen~~~y, pheno~~~,~c~rbonyl9 be~mylo;~y9 hydxo~c_yl,
hydrod~y~~~eth~~l~ -~'HO, _
CH=N~H, -C=NOHCH3, -SO3H, -S~2CH3, -S~zNH2, or when R7 are located at the
~a~tla~ position to another R;, they together form -Z;=Z~-Z~=G4- (when ein Z l
tlar ough Z4
each independently represents CH or N), -S-C~-O-, -CH=CH-~~I-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCHa-O-;
R8 through R9 are each independently hydrogen, C1_q. alkyl, C3_6 cycloallcyl,
C1_3
alkoxy, trifluoromethyl, fluoro, chloro, brorno, cyano, acetyl, amino, borono,
vitro,
carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydro~~ynaethyl, -CHO, -CH=NOH, -C=N~HCH3,-S~3H9 -SO~CH3, -SOZNH~, or when
any two R;s are located at the ortho position to each other, they together
form -Zl=Zz-
-49-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Z3=Z4- (wherein Z1 through Z4 each independently represents CH or N), -S-CO-O-
, -
CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-
S- or -O-CHzCHz-O-; and
X, Y and Z are each independently carbon or nitrogen.
In one particular embodiment of the fourth embodiment, the compounds
of the present invention are represented by formula A(TV)
wherein Rl through R9 axe each independently
(i) when comlected to a carbon atone:
hydrogen, CI_6 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, fz-butoxy, i-butoxy, sec-
butoxy, R13R14N- (wherein R13 and RI4 are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluorolnethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, nitro, carboxyl, Cl_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymethyl, -CHO,
-CH=NOH, -C=NOHCH3, -S03H, -S02CH3, -SOzNHRIS (wherein R15 is hydrogen or
C1_3 allcyl), or -O(CHz)"OR16- (wherein R16 is hydrogen or CI_3 alkyl, and n
is 1, 2 or 3);
or when any two R;s are located at the or~tho position to each other, they
together form -
~1=~z-~3=~4- (wherein ~1 through Z4 each independently represents CH or N), -S-
CO
O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N N-, -N=N-O-,
N=CH-S- or -O-CHzCHz-O-; or
(ii) when connected to a nitrogen atom;
absent;
and
X, Y and Z are each independently carbon or nitrogen;
with the proviso that
2~ w11e11 Ill=~~z=I~~=P~=I~.~=R~=h.~=R~ = hydrogen an cl ~~.=~=~=carboal; I~~
is not Cl, CN, ~CH~, NOz, CFA, H, or C~OCH~;
vrhen Rl=Rz=R3=Rq.=RS=R7=R$=leg = hydroge119 and X='~~=~=c~rlaon; RG
is not CN, NOz, or CF3;
when Ri=Rz=R3=R4=RS=R$=R~ = hydrogen, and X=Y=~=carbon; Rg sled
R7 together is not -CH=CH-CH=CH-;
when Rl=Rz=R3=R~=Rb=R~=Rg= R9=hydrogen, and X=Y=Z=carbon; RS
1S 110t OCOCH3;
when RI=R3=R~=RS=R~=R7=Rg= R9 = hydrogen, and X=Y=~=carbon;
Rz is not COOH; and
-50-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
when Rj=RZ=R3=R4=RS=R$= R9 = hydrogen, R6= Cl, and X=Y=Z=carbon;
R7 is not Cl.
In a preferred embodiment of the fourth embodiment, the compounds of
the present invention are represented by formula A(TV) wherein
Rl, R3 and R4 are each hydrogen;
RZ is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro,
carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH NOH, -
C=NOHCH3, -S03H, -SOZCH3 and -SOzNH2;
RS is:
(i) when X is nitrogen: .
absent, and
(ii) when X is carbon:
hydrogen, C1_4 alkyl, C3_s cycloallcyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH-I~TOH, -C=NOHCH3, -S~3H, -S~2CH3, -S~2NH2, or when RS are located at the
ortlao position to another R;, they together form -~~=Z2-~3=~ø- (wherein ~1
through ~4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-s-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCHZ-~-;
Rg 1S:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
h ydrogen, CI_~ a.lluyl, C~_G cyycl~alhylP C1_3 ~ll~~a~li~r,
txill~~aro~neth~l, f~a~~aro,
chloro, bromo, cyano, acetyl, amino, borono, vitro, carbo~~yl, C1_~
alko~~ycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, ben~ylo~cy, laydroa~yl, hydro~~ynzethyl, -
CH~, _
CH=NOH, -C=1VOHCH3, -S03H, -S02CH3, -S~2NH2, or when R~ are located at the
or~tlzo position to another R;, they together f~rm -ZI=~2-~3=~4- (wherein ~1
through ~4.
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CHa-O-;
R7 is:
(i) when ~, is nitrogen:
absent, and
-51-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(ii) when Z is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxyrnethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -S02CH3, -SOZNHz, or when R7 are located at the
o~tlzo position to another R;, they together form -Zl=Zz-Z3=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCHz-O-;
R$ through R9 are each independently hydrogen, C1_4 alkyl, C3_6 cycloalkyl,
Ci_3
IO alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino,
borono, nitro,
carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -CHO, -CH=NOH, -C=NOHCH3,-S03H, -SOzCH3, -SOzNHz, or when
any two R;s are located at the orth~ position to each other, they together
form -Zl=Zz-
~3=~4' (wherein Z1 through Z4 each independently represents CH or N), -S-CO-O-
, -
CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-
S- or-O-CHZCHz-O-; and
X, Y and ~ are each independently carbon or nitrogen;
with the pro~~iso that
when Rl=Rz=R3=l~=RS=R6=Rg=R9 = hydrogen, and X=Y=~=carbon; R7
is not Cl, CN, OCH3, NOz, CF3, H, or COOCH3;
when Rl=R2=R3=R4°RS=R7=R8=R9 = hydrogen, and X=Y=Z=carbon; R6
is not CN, NOz, or CF3;
when Rl=Rz=R3=R~=RS=R8=R9 = hydrogen, and X=Y=~=carbon; R6 and
R7 together is not -CH=CH-CH=CH-;
2~ ~,~hen P~I=I~.z=Rj=p~=~~=hey=p'~.a= F~,=hy~lrogen~ and %'~=~=v=carbon; Ry
is not OCOCH~;
when Rl=1~.~=R4=RS=R~=R7=R$= R9=hydrogen, and ~=1~=~=carbon; Rz
is not COON; and
when Rl=Rz=R3=l~=RS=R8= R9=hydrogen, RG= Cl, and ~i=Y=~=carbon;
R7 is not Cl.
'"able ~~: l~ep~resentatg~re C'~anp~t~a~d~s au F~~-~~la ~(~~):
-52-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Rl R2 R3 R4 Rs Rs R7 R8 R9 X Y Z
H COON H H F H H H H C C C
H COOH H H Cl H H H Cl C C C
H NOz H H Cl H H H Cl C C C
H H H H Cl H H H Cl C C C
Formula A(V)
In a fifth embodiment, the compounds of the present invention are
represented by formula A(V):
R~
R2
R8
Ry
vUherein R1 through R9 are each independently hydrogen, C1_6 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, ra-butoxy, i-butoxy, see-butoxy, Rl3RiaN- (v~herein
R13 alld Rla
each independently represents hydrogen or C1_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, vitro, amino, borono,
carboxyl,
C1_6 allcoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
tuirrmth~~lsilylo~~y, diphenyl-t-butylsilyloxy, hydroxymethyl, -SO~H, -SOZCH3,
-
SOZ1~~IRls (herein R;5 is hydrogen or C1_~ alkyl), or -O(CH~)"~Rl~- (-~rherein
R1~ is
hydrogen or C1_3 alkyl, and n is l, 2 or 3); or when any two R;s are located
at the ~~-Eda~
position to each other, they together form-~1=~~-~~_~~- (wherein ~1 through ~4
each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCH2-O-.
In a preferred embodiment of the fifth embodiment,
Rl and R4 are each hydrogen;
-53-
HO~ OOH
B
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
RZ and R3 are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, amino, borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-SO3H, -SO~CH3 and -SOZNH2;
RS through R9 are each independently hydrogen, C1_4 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
borono, vitro, carboxyl, Cl_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
ber~yloxy, hydroxyl, hydroxymethyl, -SO3H, -SOZCH3, -SOZNHZ, or when any two
R;s
are located at the o~tho position to each other, they together form -~1=Z2-
Z3=Z4-
(wherein Zl through ~4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N N-, -N N-O-, -N=CH-S- or -O-
CH2CH2-O-.
In one particular embodiment of the fifth embodiment, the compounds of
the present invention are represented by formula A(V):
wherein Rl through R9 are each independently hydrogen, C1_6 alkyl, C3_6
cycloalkyl, Ci_3 alkoxy, f2-butoxy, i-butoxy, sec-butoxy, R13R1aN- (wherein
R13 and R14
each independently represents hydrogen or C1_3 allcyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, vitro, amino, borono,
carboxyl,
C1_6 alkoxycaxbonyl, phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -S02CH3, -
SOZNHR15 (wherein Rls is hydrogen or C1_~ alkyl), or -O(CH2)"ORI6- (wherein
Rt~ is
hydrogen or C1_3 allcyl, and n is 1, 2 or 3); or when any two R;s are located
at the ~r~tlao
position to each other, they together form -~;1=~2-Z~=~4- (wherein ~i through
~4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N=N-~-, -N=CH-S- or -O-CHZCH~-O-;
with the proo~aso that
when R;=RZ=R~=R4=RS=R6=Rg=R~ = hydrogen; R~ is not H, OH or
C (~;H~)3 a
In another embodiment of the fifth embodiment,
Ri and R4 are each hydrogen;
Ra and R3 are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, amino, borono, vitro, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-S03H, -SO~CH3 and -SOaNH2;
R~ through R~ are each independently hydrogen, C1_~ alkyl, C~_~
cycloalkyl, Ci_3 alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano,
acetyl, amino,
-54-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
borono, nitro, carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
benzyloxy, hydroxyl, hydroxymethyl, -S03H, -SOZCH3, -S02NHz, or when any two
R;s
are located at the o~tlzo position to each other, they together form -Zl=ZZ-
Z3=Z4-
(wherein Zl through Z4 each independently represents CH or N), -S-CO-O-, -
CH=CH-
NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N N-O-, -N=CH-S- or -O-
CHZCHZ-O-;
with the proviso that
when R~=RZ=R3=R4=RS=R6=R8=R9 = hydrogen; R~ is not H, OH or
C(CH3)3.
Non-limiting specific compounds described by formula A(V) are listed in
Table 5.
Table S: Representative Compounds in Formula A(V):
Rl RZ Rs Ra Rs ~ R7 Rs R9
H H H H H H H H H
H F H H H NOz H H H
H F Ii H H Cl H H H
H H H H H Cl H H H
H H H H H N02 H H H
H
Compound (compound F1002)is available from C~mbi-
~lochs, Inc. ( San Diego, California, Cat. hTo. ~F-21140.
Formula A(VI)
In a sixth embodiment, the compounds of the present invention are
represented by formula A(VI):
-55-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(Compound F1212).
This compound is available from Combi-Blocl~s, Inc. (San Diego,
California, Cat. No. BB-2162).
Formula A(VII~
In a seventh embodiment, the compounds of the present invention are
represented by formula A(VII):
A(VII)
S~Q
\c
Wherein Q is oxygen or lone-pair electrons.
HO~ ,OH
B
The compound ~ s ~ (compound F1012)is available from
Sigma-Aldrich, Inc. (St. Louis, Ie~~, Cat. No. 51221-4.
Fo~°I~~aula ~~~~~I~
In an eighth embodiment, the compounds of the present invention axe
represented by formula ~2(~III):
H~~ OOH
B
A(VIII)
(compound BB-loop).
-56-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Compound BB-1003 is commercially available from Combi-Blocks, Inc.
(San Diego, California, Cat. No. BB2I I9).
Formula A(IX)
In a ninth embodiment, the compounds of the present invention are
represented by formula A(IX):
HO~ OOH
B
A(IX)
O
° ~ (compound BB-1004).
Compound BB-1004 is commercially available from Combi-Blocks, Inc.
(San Diego, California, Cat. No. BB2623).
Formula A(~)
In a tenth embodiment, the compounds of the present invention are
represented by formula A(X):
HO~ /OH
(compound BB-1005).
Compound BB-1005 is commercially available from Combi-Blocks, Inc.
(Seal Diego, California , Cat. No. BB3052).
~~ ~r a~~ul~ .~(~~ll l
In an eleventh embodiment, the compounds of the present invention are
represented by formula A(~~l':
wherein ICI is hydrogen, Cl_~ allcyl, C3_~ cycloalkyl, C1_3 alko~y, aa-butoxy,
i_
butoxy, sec-buto~y, I~131214N- (wherein R13 and 1214 are each independently
hydrogen or
-57-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Ci-s alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro,
chloro, bromo,
cyano, acetyl, amino, borono, nitro, carboxyl, C1_6 alkoxycarbonyl, phenyl,
phenoxy,
phenoxycarbonyl, benzyloxy, hydroxyl, trimethylsilyloxy, diphenyl-t-
butylsilyloxy,
hydroxymethyl, -S03H, -SOZCH3, -SOzNHRIS (wherein RIS is hydrogen or C1_3
alkyl), or
-O(CHz)"OR16- (wherein R16 is hydrogen or C1_3 alkyl, and n is 1, 2 or 3).
In a preferred embodiment of the eleventh embodiment,
Rl is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitro,
carboxyl, Ci_4 alkoxycarbonyl, phenoxycarbonyl, hydroxyl, -S03H, -SO2CH3 and -
SOzNHz.
In one particular embodiment of the eleventh embodiment, the
compounds of the present invention are represented by formula A(XI),
wherein Rl is Cl_6 alkyl, C3_6 cycloalkyl, C~_3 alkoxy, rz-butoxy, i-butoxy,
sec-
butoxy, R13RI4N- (wherein R13 and R14 are each independently hydrogen or C1_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOZCH3, -
SOzNHRIS (wherein R15 is hydrogen or C1_3 alkyl), or -O(CHz)"OR16- (wherein
RI6 is
hydrogen or C1_3 alkyl, and n is l, 2 or 3).
In another embodiment of the eleventh embodiment,
RI is fluoro, chloro, bromo, cyano, acetyl, carboxyl, C1_4 alkoxycarbonyl,
phenoxycarbonyl, hydroxyl, -S03H, -SOzCH3 and -SOzNHz.
Non-limiting specific compounds described by formula A(XI) are listed in
Table 6.
~Cablc ~: ~cpresentative ~0mp~uud~ in F~rrraula A(~I):
~I
~2
H
OH
CN
Br
~~x~~a~ata ~~~I)
-58-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
In a twelfth embodiment, the compounds of the present invention are
represented by formula A(XII):
XII)
~R6
Y
Z~
R~
wherein RI through R9 are each independently
(i) when connected to a carbon atom:
hydrogen, Ci-s alkyl, C3_6 cycloalkyl, C1_3 alkoxy, n-butoxy, i-butoxy, sec-
butoxy, Rl3RIaN- (wherein R13 and Rj4 are each independently hydrogen or CI_3
alkyl),
trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,
cyano, acetyl,
amino, borono, nitro, carboxyl, C1_6 alkoxycarbonyl, phenyl, phenoxy,
phenoxycarbonyl,
ben~yloxy, hydroxyl, trimethylsilyloxy, Biphenyl-t-butylsilyloxy,
hydroxymetlayl, -CHO,
-CH NOH, -C=NOHCH3, -S03H, -SOZCH3, -SOZNHRis (wherein RIS is hydrogen or
C1_3 alkyl), or -O(CHZ)"OR16- (wherein R16 is hydrogen or C1_3 alkyl, and n is
1, 2 or 3);
or when any two R;s are located at the e~~°th.~ position to each other,
they together form -
~1=~2-~3-~4- (wherein Zl through Z~ each independently represents CH or N), -S-
C~-
~-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-~-, -N=CH-NH-, -CIIZ-N IV-, -N=N-O-, -
N=CH-S- or -O-CHZCHz-~-; or
(ii) when connected to a nitrogen atom;
absent;
and
X, ~ and ~ are each independently carbon or nitrogen.
In a preferred embodiment of the twelfth embodiment,
Rl, R3 and R4 are each hydrogen;
RZ is hydrogen, fluoro, chloro, bromo, cyano, acetyl, amino, nitro, carboxyl,
C1_4
allcoxycarbonyl, phenoxycarbonyl, hydroxyl, -CHO, -CH=NOH, -C=NOHCH3, -S03H, -
SOZCH3 and -SO2NH2;
RS IS:
-59-
HO~ /OH
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(i) when X is nitrogen:
absent, and
(ii) when X is carbon:
hydrogen, C1_4 alkyl, C3_s cycloalkyl, C1_3 alkoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, C1_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydr~xymethyl, -S03H, -
SO~CH3, -SO2NH2, or when RS are located at the of~tlzo position to another R;,
they
together form -~1=~2-~3=~4- (wherein ZI through ~4 each independently
represents CH
or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N=N , -
N=N-O-, -N=CH-S- or -O-CH2CH2-O-;
RG is:
(i) when Y is nitrogen:
absent, and
(ii) when Y is carbon:
hydrogen, C1_4 alkyl, C3_6 cycloalkyl, C1_3 allcoxy, trifluoromethyl, fluoro,
chloro, bromo, cyano, acetyl, amino, borono, nitro, carboxyl, CI_4
alkoxycarbonyl,
phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl, hydroxymethyl, -CHO, -
CH=NOH, -C=NOHCH3, -S03H, -S02CH3, -S~2NH2, or when R6 are located at the
~~~tho position to another R;, they together form -~1=Za-~3=Zq.- (wherein ~,1
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -
CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCH2-O-;
R7 is:
(i) when ~ is nitrogen:
absent, and
(ii) ~,rhen ~ is carbon:
hydrogen, C1_4 alkyl, C3_g cycloalkyl, C1_3 alkoa~y, trif~uoromethyl, fluoro,
chloro, bronmo, cyano, acetyl, amino, borono, vitro, carbo~~yl, C1_4
~lko~~yycarbcanyl,
phenyl, phenoxy, phenoxycarbonyl, ben~yl~~~y, hydroxyl, hydroxymethyl, -CHO,
CH=NOH, -C=NOHCH3, -SO3H, -SOZCH3, -SO2NH2, or when R~ are located at the
o~tho position to another R;, they together form -Z;=Z~-~~=Z4- (wherein Zl
through Z4
each independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-,
CH=CH-O-, -N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CH~CHa-O-;
R$ through 1:.9 are each indepezidently hydrogen, C1_4 alkyl, C~_~
cycloallcyl, C1-s
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
vitro,
-60-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -CHO, -CH=NOH, -C=NOHCH3, -S03H, -SO2CH3, -SO2NH2, or when
any two R;s are located at the ortlao position to each other, they together
form -Zl=Zz-
~3'~4- (wherein Zl through Z4 each independently represents CH or N), -S-CO-~-
, -
CH=CH-NH-, -CH=CH-S-, -CH=CH-O-, -N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-
S- or -O-CHZCH2-O-; and
X, Y and Z are each independently carbon or nitrogen.
Non-limiting specific compounds described by formula A(XII) are listed
in Table 7.
Table 7: Representative Compounds in Formula A(XII):
Ri Rz R3 R4 RS Rg R7 R8 R9 X Y Z
H H H H Cl H H H Cl C C C
H H H H Cl H Cl H Cl C C C
H H H H H H H H H C N C
H NOZ H H Cl H ~ H H Cl C C
~ ~ ~ ~ ~ ~ ~ ~ ~
Formula A~II)
In a thirteenth embodiment, the compounds of the present invention are
represented by formula A(XIII):
~~xtlr~
wherein I~1 through R1a are each independently hydrogen, C1_~ alkyl, C3_~
cycloalkyl, Cl_3 alkoxy, f~.-butoxy, i-butoxy, sic-butoxy, Rl3RiaN- (wherein
I~;3 and Rla.
are each independently hydrogen or C~_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
C1_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SOa,CH3, -
SOZNHRIS (wherein RIS is hydrogen or C1_3 alkyl), or -O(CH2)"~I~1~- (wherein
1216 is
-61-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the o~~tho
position to each other, they together form -Zl=Z2-Z3=Z4- (wherein Zi through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CHaCH2-O-.
Tn a preferred embodiment of the thirteenth embodiment,
Rl, R3, R4, R9, Rl l and R12 axe each hydrogen;
RZ and Rlo are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl,
nitro, amino, borono, carboxyl, Cl_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl, -S03H,
-SOZCH3 and -SOZNH2;
RS through R8 are each independently hydrogen, Ci_4 alkyl, C3_~ cycloalkyl,
C1.3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
nitro,
carboxyl, Cz_~ alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -S03H, -SO2CH3, -SO2NH2, or when any two R;s are located at the
oYtho
position to each other, they together form -ZI=Z2-Z3=Z4- (wherein ZI through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CHz-O-.
Non-limiting specific compounds described by formula A(NIII) axe listed
in 'Table 8.
'able ~: Representative Compounds in Formula A(ILI):
l~~R2 R~ R4 Rs ~6 ~7 RB R9 Rlo Ian Ria
H F H H CI H H H F H H H
H F H H H H H H F H H H
H H H H CI H H H Ii H H H
H H H H H H H H H H H H
'~ ~r naula ~~~~L~
In a fourteenth embodiment, the compounds of the present in~rention are
represented by formula A(~IV):
-62-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
wherein RI through Rg are each independently hydrogen, Cl_6 alkyl, C3_6
cycloallcyl, C1_3 alkoxy, ra-butoxy, i-butoxy, sec-butoxy, R13Ri4N- (wherein
R13 and R14
each independently represents hydrogen or Cl_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, nitro, amino, borono,
carboxyl,
C1_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOzCH3, -
SOZNHR15 (wherein Rls is hydrogen or C1_3 alkyl), or -O(CH2)"OR16- (wherein
R16 is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the ~rtlZo
position to each other, they together fornz -~t=~Z-~3=,~4" (~~herein ~1
through ~4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or-O-CH2CH2-O-.
In a preferred embodiment of the fourteenth embodiment,
RI and R4 are each hydrogen;
RZ and 123 are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl,
amino, borono, nitro, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl, -S03H,
-SO~CH3 and -SO2NH2;
RS through R~ are each independently hydrogen, CI_4 alkyl, C3_~ cycloall~yl,
G1_3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
nitro,
2Cl carboxyl, C1~ alkoxycarbonyl, phenyl, phenoxy9 phenos~ycarbonyl,
ben~yloxy, hydroxyl,
hydroxymethyl, -SO3H, -SOZCH3, -SOZI~IHz, or when any two R;s are located at
the c~°th~
position to each other, they together form -Zl=Z2-Z3=Z4- (wherein Zl through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CH2-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-.
Non-limiting specific compounds described by formula A(XI~T) are listed
in Table 9.
-63-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Table 9: Representative Compounds in Formula A(XIV):
Rl R2 R3 R4 Rs R6 R~ R8 R9 Rio Rm Ri2
H F H H Cl H H H NOZ H H H
H F H H Cl H H H Cl H H H
H H H H Cl H H H Cl H H H
Formula A(XV)
Tiz a fifteenth embodiment, the compounds of the present invention are
represented by formula A(XV):
Nn nN
R~~
R11
wherein I~1 through I~12 are each independently hydrogen, C1_~ alkyl, C3_~
cycloallcyl, C1_3 alkoxy, aa-butoxy, a-butoxy, sec-butoxy, R13Iy4N- (wherein
113 and lya
are each independently hydrogen or C1_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, nitro,
carboxyl,
C1_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, ben~yloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -S~3H, -S~ZCH3, -
5~~1~:1~II~eI~ (~rherein I~ls is hydrogen ~r ~.'1_~ all~yl)9 or -C(CHZ)"~I~1~-
(wherein I~.Ib is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two I~;s are located
at the ~f~tlr~
position to each otherP they together form-~I=~~-~3=~4- (wherein ~1 through ~4
each
independently represents CH or I~T)~ -S-CC-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-~-
,
-N=CH-NH-, -CHZ-N=N-, -N=N-~-, -N=CH-S- or -~-CHZCHZ-~-.
In a preferred embodiment of the fifteenth embodiment,
Rl, R3, I~, I29, Rlt and Iyz are each hydrogen;
-64-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
RZ and Rlo are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl,
nitro, amino, borono, carboxyl, C1_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl, -S03H,
-SOZCH3 and -S~ZNH2i
RS through R8 are each independently hydrogen, C1_4 alkyl, C3_6 cycloallcyl,
C1-3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
nitro,
carboxyl, C1_4 allcoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -S03H, -SOZCH3, -SOZNHZ, or when any two R;s axe located at the
oYtho
position to each other, they together form -Zl=Z2-Z3=Z4- (wherein Zl through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-.
Non-limiting specific compounds described by formula A(XV) are listed
in Table 10.
Table 10: Representative Compounds in Formula A(XV~:
Rl R2 R3 R4 RS R6 R7 R8 R9 R10 Rll R12
H NOZ H H H H H H H NOZ H H
H NOZ H H H ~r H H H NO2 H H
H NOZ H H COCH3 H H H H NOa H H
H NOa H H H H COOH H H NOa H H
H H H H H H H H H H H H
H H H H H Br H H H H H H
H H H H COCH3 H H H H H H H
H H H H H H COOH H H H H H
lEorm~ala ~(~~Tt1)
In a sixteenth embodiment, the compounds of the present invention are
represented by formula A(~VI):
-65-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Rio
A(XVI)
Rm
wherein R1 through Rlz are each independently hydrogen, C1_6 alkyl, C3_6
cycloalkyl, C1_3 alkoxy, h-butoxy, i-butoxy, sec-butoxy, R13R14N- (wherein R13
and Rla
are each independently hydrogen or CI_3 alkyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
C1_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SOzCH3, -
SOzNHRIS (wherein Rls is hydrogen or C1_3 allcyl), or -O(CHz)"ORI6- (wherein
R16 15
hydrogen or C1_3 alkyl, and n is 1, 2 or 3); or when any two R;s are located
at the ortho
position to each other, they together fonn -Zl=Z2-Z3°Z4- (wherein Zl
through Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHzCH2-O-.
In a preferred embodiment of the sixteenth embodiment,
Rl, R3, R4, R9, Rl1 and Rlz are each hydrogen;
Rz and Rlo are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl,
vitro, amino, borono, carboxyl, Ci_4 allcoxycarbonyl, phenoxycarbonyl,
hydroxyl, -SO3H,
-SOzCH3 and -SOzNHz;
P~~ through Rg are each indelaendently hydrogen9 ~'1_~ all~.yl, C3_~
cycloalkyl, C1_~
allcoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
vitro,
2Q carboxyl, C1_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl,
ben~ylo~cy, hydroxyl,
hydro~~ylnethyl, -SO~H, -SOzCH3, -SOzI~THz, or when any two R;s are located at
the ~a~th~
position to each other, they together form -~,1=~z-~3=~4- (wherein ~,r through
~4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHz-N=N-, -N=N-O-, -N=CH-S- or -O-CHZCHz-O-.
Non-limiting specific compounds described by formula A(XVI) are listed
in Table 10A.
Table 10I~ ~epre~eratati~e C~arlp~azn~l~ i~l ~'~t-a~ula A(~~V~)
-66-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Rl Rz R3 R4 Rs Rg R~ R8 R9 Ri Ri Ri
o i z
H NOz H H H H H H H N02 H H
H H H H H H H H H H H H
Formula A(XVII)
In a seventeenth embodiment, the compounds of the present invention are
represented by formula A(XVII):
A(XVII)
wherein RI through RIa are each independently hydrogen, CI_6 alkyl, C3_s
cycloallcyl, C1_3 allcoxy, rz.-butoxy, i-butoxy, sic-butoxy, RI3RIaN- (wherein
RI3 and RI4
are each independently hydrogen or C1_3 allcyl), trifluoromethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
Cl_6 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, bemyloxy, hydroxyl,
trimethylsilyloxy, Biphenyl-t-butylsilyloxy, hydroxymethyl, -S03H, -SOzCH3, -
SOZhTHRIS (wherein RIS is hydrogen or CI_3 alkyl), or -O(CHz)"ORI~- (wherein
RI6 is
hydrogen or C1_3 alkyl, and n is 1, 2 or 3)9 or when any two R;s are located
at the oYtlz~
position to each other, they together forru -~~=~2-~~=~q- (wherein ~1 thr~llgh
~q. each
independently represents CH or 1~~, -S-CO-O-, -CH=CH-I~-I-, -CH=CH-S-, -CH=CH-
O-,
-N=CH-NH-, -CHz-N=~T-, -N=1'~T-O-, -1~T=CH-S- or -O-CHZCHz-O-a
In a preferred embodiment of the sixteen th embodiment,
RI, R3, Rq., R9, RII and R;z are each hydrogen;
Rz and RIO are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl,
vitro, amino, borono, carboxyl, C1_4 allcoxycarbonyl, phenoxycarbonyl,
hydroxyl, -S03H,
-S02CH3 and -SOaNH2a
RS through R8 are each independently hydrogen, C1_4 alkyl, C3_6 cycloalkyl,
C1_3
alkoxy, trifluorornethyl, floor~, chloro, br~mo, cyan~, acetyl, amin~, borono,
vitro,
-67-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
carboxyl, CI_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -S03H, -S02CH3, -SO2NH2, or when any two R;s are located at the
o~tho
position to each other, they together form -ZI=ZZ-Z3=Z4- (wherein ZI through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CH~CH2-O-.
Non-limiting specific compounds described by formula A(XVII) are
listed in Table IOB.
Table 10B Representative Compounds in Formula A(XVII)
Rl R2 R3 R4 R$ R6 R7 R8 R9 Rl Ri Ri
o i a
H NO2 H H H H H H H NOZ H H
H H H H H H H H H H H H
Formula A(XVIII)
In a eighteenth embodiment, the compounds of the present invention are
represented by formula A(XVIII):
0
A(XVIII)
a
~c~rherein Rl through R~o are each independently hydrogen, Ci_6 alkyl, C3_6
cycloalkyl, CI_~ allcoxy, ~a-buto~~y, ~-butoxy, sec-butoxy, RI3RI4N- (wherein
R13 and RIq.
are each independently hydrogen or CI_3 alkyl), trifluorornethyl,
trifluoromethoxy,
difluoromethoxy, fluoro, chloro, bromo, cyano, acetyl, amino, borono, vitro,
carboxyl,
CI_~ alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy, hydroxyl,
trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl, -SO3H, -SOZCH3, -
SO~~RI~ (wherein RIS is hydrogen or CI_3 alkyl), or -O(CH2)"ORIG- (wherein RIG
is
-68-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
hydrogen or CI_3 alkyl, and n is 1, 2 ox 3); or when any two R;s are located
at the o~tlao
position to each other, they together form -Zl=Z2-Z3=z4- (wherein ZI through
Z4 each
independently represents CH or N), -S-CO-O-, -CH=CH-NH-, -CH=CH-S-, -CH=CH-O-,
-N=CH-NH-, -CHZ-N=N-, -N=N-O-, -N=CH-S- or -O-CH2CH2-O-.
In a prefelTed embodiment of the eighteenth embodiment,
RI, R3, R4, R9, RII, Ri2, Ri7, RI9 and R2o are each hydrogen;
Ra, RIO and RI$ are each independently hydrogen, fluoro, chloro, bromo, cyano,
acetyl, nitro, amino, borono, carboxyl, CI_4 alkoxycarbonyl, phenoxycarbonyl,
hydroxyl,
-S03H, -S02CH3 and -SO2NH2;
RS through R7 are each independently hydrogen, CI_4 alkyl, C3_6 cycloallcyl,
C1_3
alkoxy, trifluoromethyl, fluoro, chloro, bromo, cyano, acetyl, amino, borono,
vitro,
carboxyl, CI_4 alkoxycarbonyl, phenyl, phenoxy, phenoxycarbonyl, benzyloxy,
hydroxyl,
hydroxymethyl, -S03H, -SO2CH3, -SOaNH2.
Non-limiting specific compounds described by formula A(XVIIT) are
listed in Table l OC.
'Table lOC Representative C0rnp0unds in b'0mnula A(XVIII)
~1 ~2 ~3 ~ ~~ ~ ~'7 ~9 X10 X11 ~12 ~17 ~1~ X19 ~20
H NO2 H H H H H H N02 H H H N02 H H
H H H H H H H H H H. H H H H H
~-Laaeta~ase~
The compounds of the present invention can be used to inhibit any j3-
lactamases.
,~-hctamases are endogelaous bacterial el~ymes that destroy,-IactHrl
antibiotics and ~1I1111nat~ their efficacy. The mane derives from their
ability to cleave the
,~-lactaln ring. The stI-dlctures of many ~'-lactamases are l~.nown at the
atomic level and
available iI~I the protein database. Preferably, the ,~-lactamase is a Class
~, ~, C or D ~-
lactamase. I~Lore preferably, it is a Class A (TEI~1) or Class C (AmpC) ,Q-
Iactamase.
Salts and Derivatives
Various pharmaceutically acceptable salts, ether derivatives, ester
derivatives, acid derivatives, and aqueous solubility altering derivatives of
the active
compound also are encompassed by tlae present invention. 'The present
invention further
includes all individual enantiomers, diastereomers, racemates, and other
isomer of the
-69-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
compound. The invention also includes all polymorphs and solvates, such as
hydrates
and those formed with organic solvents, of this compound. Such isomers,
polymorphs,
and solvates may be prepared by methods known in the art, such as by
regiospecific
and/or enantioselective synthesis and resolution, based on the disclosure
provided herein.
Suitable salts of the compound include, but are not limited to, acid
addition salts, such as those made with hydrochloric, hydrobromic, hydroiodic,
perchloric, sulfuric, nitric, phosphoric, acetic, propiouc, glycolic, lactic
pyruvic,
malonic, succinic, malefic, fumaric, malic, tartaric, citric, benzoic,
carbonic cinnamic,
mandelic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic,
benezenesulfonic, p-
toluene sulfonic, cyclohexanesulfamic, salicyclic, p-aminosalicylic, 2-
phenoxybenzoic,
and 2-acetoxybenzoic acid; salts made with saccharin; alkali metal salts, such
as sodium
and potassium salts; alkaline earth metal salts, such as calcium and magnesium
salts; and
salts formed with organic or inorganic ligands, such as quaternary ammonium
salts.
Additional suitable salts include, but are not limited to, acetate,
benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate,
bromide, calcium
edetate, camsylate, carbonate, chloride, clavulanate, citrate,
dihydrochloride, edetate,
edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate,
glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide,
hydrochloride,
hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate,
malate, maleate,
mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mueate,
napsylate,
nitrate, ICI-methylglucamine annnonium salt, oleate, pamoate (embonate),
palmitate,
pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate,
sulfate,
subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and
valerate salts of
the compound of the present invention.
~a-odm~gs atld active nmtabolites ~f con ~lao~nds dis~cl~ased lmr ein are also
within the scope of the invention.
A prodrug is a pharmacologically inactive compound that is converted
into a phauma~cologically active agent by a metabolic transformation. Iaa
vii,~, a prodrug
is acted on by naturally occurring enzymes) resulting in liberation of the
pharmacologically active agent. Conventional procedures for the selection and
preparation of suitable prodrug derivatives are described, for example, in
"Design of
Prodrugs", ed. H. Bundgaard, Elsevier, 195.
-70-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
An active metabolite is a compound which results from metabolism of
another compound after administration of the latter to a subject. Metabolites
can be
identified by techniques well-known in the art.
Formulation and Administration
Suitable dosage forms include but are not limited to oral, rectal, sub-
lingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous,
transdermal, spinal, intrathecal, infra-articular, intra-arterial, sub-
arachinoid, bronchial,
lymphatic, and infra-uterille administration, and other dosage forms for
systemic delivery
of active ingredients.
To prepare such pharmaceutical dosage forms, one or more of the
aforementioned compounds of formula (1), alone or in combination with (3-
lactam
antibiotics, are intimately admixed with a pharmaceutical carrier according to
conventional pharmaceutical compounding techniques. The carrier may take a
wide
variety of forms depending on the form of preparation desired for
administration.
In preparing the compositions in oral dosage form, any of the usual
pharmaceutical media may be employed. Thus, for liquid oral preparations, such
as, for
example, suspensions, elixirs and solutions, suitable carriers and additives
include water,
glycols9 oils, alcohols, flavoring agents, preservatives, coloring agents and
the like. For
solid oral preparations such as, for example, powders, capsules and tablets,
suitable
carriers and additives include starches, sugars, diluents, granulating agents,
lubricants,
binders, disintegrating agents and the like. I~ue to their ease in
administration, tablets
and capsules represent the most advantageous oral dosage unit form. If
desired, tablets
may be sugar coated or enteric coated by standard techniques.
For parenteral formulations, the carrier will usually comprise sterile
v,~ater~ though other ingredieuts~ for e~~an~ple~ ilagredients that aid
solubility or fear
preservation, may be included. Injectable solutions may also be prepared in
which case
appropriate stabilising agents may be employed.
In some applications, it may be advantageous to utilise the active agent in
a "vectorized" form, such as by encapsulation of the active agent in a
liposome or other
encapsulant medium, or by fixation of the active agent, e.g., by covalent
bonding,
chelation, or associative coordination, on a suitable biomolecule, such as
those selected
from proteins, lipoproteins, glycoproteins, and polysaccharides.
Treatment methods of the present invention using formulations suitable
for oral administration may be presented as discrete units such as capsules,
cachets,
-71-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
tablets, or lozenges, each containing a predetermined amount of the active
ingredient as a
powder or granules. Optionally, a suspension in an aqueous liquor or a non-
aqueous
liquid may be employed, such as a syrup, an elixir, an emulsion, or a draught.
A tablet may be made by compression or molding, or wet granulation,
optionally with one or more accessory ingredients. Compressed tablets may be
prepared
by compressing in a suitable machine, with the active compound being in a free-
flowing
form such as a powder or granules which optionally is mixed with a binder,
disintegrant,
lubricant, inert diluent, surface active agent, or discharging agent. Molded
tablets
comprised of a mixture of the powdered active compound with a suitable carrier
may be
made by molding in a suitable machine.
A syrup may be made by adding the active compound to a concentrated
aqueous solution of a sugar, for example sucrose, to which may also be added
any
accessory ingredient(s). Such accessory ingredients) may include flavorings,
suitable
preservative, agents to retard crystallization of the sugar, and agents to
increase the
solubility of any other ingredient, such as a polyhydroxy alcohol, for example
glycerol or
sorbitol.
Formulations suitable for parenteral administration usually comprise a
sterile aqueous preparation of the active compound, which preferably is
isotonic with the
blood of the recipient (e.g., physiological saline solution). Such
formulations may
include suspending agents and thickening agents and liposomes or other
microparticulate
systems which are designed to target the compound to blood components or one
or more
organs. The formulations may be presented in unit-dose or mufti-dose form.
Parenteral administration may comprise any suitable form of systemic
delivery or delivery directly to the CI~TS. Administration may for example be
intrawenou~, intra-anterial9 ntrathecal9 intramuscular~ s~.~bcutaneod2s~
i~~tran~a~sculaz~ intr~-
abdominal (e.g., intraperitoneal), etc., and may be effected by infusion pumps
(es~ternal
or implantable) or any other eatable means appropriate to the desired
administration
modality.
Nasal and other mucosal spray formulations (e.g. inhalable forms) can
comprise purified aqueous solutions of the active compounds with preservative
agents
and isotonic agents. Such formulations are preferably adjusted to a pH and
isotonic state
compatible with the nasal or other mucous membranes. Alternatively, they can
be in the
form of finely divided solid powders suspended in a gas carrier. Such
formulations may
-72-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
be delivered by any suitable means or method, e.g., by nebulizer, atomizer,
metered dose
inhaler, or the like.
Formulations for rectal administration may be presented as a suppository
with a suitable carrier such as cocoa butter, hydrogenated fats, or
hydrogenated fatty
carboxylic acids.
Transdermal formulations may be prepared by incorporating the active
agent in a thixotropic or gelatinous carrier such as a cellulosic medium,
e.g., methyl
cellulose or hydroxyethyl cellulose, with the resulting formulation then being
packed in a
transdermal device adapted to be secured in dermal contact with the skin of a
wearer.
W addition to the aforementioned ingredients, formulations of this
invention may further include one or more accessory ingredients) selected from
diluents, buffers, flavoring agents, binders, disintegrants, surface active
agents,
thickeners, lubricants, preservatives (including antioxidants), and the like.
The formulation of the present invention can have immediate release,
sustained release, delayed-onset release or any other release profile known to
one skilled
in the art.
R-~acta~W.ntibi~~ics
~3-lactam antibiotics are compounds with antnnicrobial activities and
contain the ,~-lactam structure. piny (~-lactam antibiotic is suitable.
ll~Iany suitable X3-
lactam antibiotics are known (See e.g., l~. ~. I~Iorin and IVI. Caorin,
IiiLEds.9 Academic
Press, New York, 192; vol. 1-3). These include but not limited to
cephalosporins (e.g.,
cephalothin), penicillins (e.g., amoxicillin), monobactams (e.g., aztreonam),
carbapenems (e.g., imipenem), carbacephems (loracarbef), and others. ~-lactam
antibiotics are effective (in the absence of resistance) against a wide range
of bacterial
izifecti~am. These in elude those ca~~se~ by gram-p~siti~re aW/~r gram-
negaxi~e bacteria,
for e~~aanple9 bacteria of the genus ~'tezpla~rl~c~ccads (such as
~'taplz~rlcc~ceus aass~e~rs and
rS'taplr~rl~c~accus cpidea~a~iis), ~'toept~aceccars (such as Stf~e~at~ceaccus
agalacti~ae,
~'tr~ept'~e~ceus peazurra.~t~iae and bS"t~~ept~c~ccus faccalis),
I~lic~~c~ccz~s (such as
ll~Iicr~eoccus lutcus), Bacillus (such as Bacillus subtilis), Listef~ella
(such as Listc~ella
mosa~cytogefaes), Esch.ericlaia (such as Esclaet~ichia coli), I~lebsiella
(such as Klebsiella
p~euna~yaiae), Proteus (such as P~oteus ryairabilis and P~oteus vulgaris),
.Salr~aoraella
(such as ~'alnaofaella typhosa), Slaigella (such as Shigella sonraei),
Erz.ter~bacter (such as
Eazte~obacte~ aef~c~gcaaes and ~°fatet~~baete~, faciu~z), ~'ey~y-atia
(such as ~Sery-atia
rnaf°cescehs), Pseudomofzas (such as Pseudornoraas ae~ugifzosa),
Acirzetobactei° such as
-73-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Acitaetobacter anitratus), NocaYdia (such as Nocaf~dia autotrophica), or
Mycobacte~~ium
(such as Mycobacteriufn fortuituyn). Preferred ~i-lactam antibiotics are those
which
preferentially deactivated by Class A and Class C ~3-lactamase enzymes, for
example,
amoxicillin, piperacillin, ampicillin, ceftizoxime, cefotaxime, cefuroxime,
cephalexin,
cefaclor, cephaloridine, and ceftazidime. Effective doses and modes of
administration of
~i-lactam antibiotics, alone or in combination with (3-lactamase inhibitor(s),
are known in
the art or may be determined empirically by one skilled on the art.
Combination Treatments
The compounds disclosed herein may be used in combination with with
one or more other antibacterial agent for any of the aforementioned methods,
including
without limitation, any of the aforementioned methods of treatment. Preferred
classes of
antibacterial agents for use in combination with the compounds disclosed
herein axe,
without limition, (3-lactam antibiotics, described supf°a,
fluoroquinolones, quinolones,
macrolides, and tetracyclines. Examples of fluoroquinolones include, without
limitation,
ciprofloxacin, clinafloxacin, enoxacin, fleroxacin, gatifloxacin,
moxifloxacin,
gemifloxacin, grepafloxacin, levofloxacin, norfloxacin, sparfloxacin, and
trovafloxacin.
Examples of quinolones include, without limitation, cinoxacin, garenoxacin,
and
nalidixic acid. Examples of lnacrolides include, without limitation,
azithromycin,
clarithromycin, dirithrolnycin, erythromycin, and lincomycin. Examples of
tetracyclines
include, without limitation, doxycycline, mlnocycllne, and tetracycline.
The term "in combination" refers to the concomitant administration of two (or
more) active agents for the treatment of a, e.g., single disease state. As
used herein, the
active agents may be combined and administered in a single dosage form, may be
administered as separate dosage forms at the same time, or may be administered
as
selaar~.te dosage folxlm that are adlnirlistered altel-lmtely gar
seq~~ea~ataally rlv tlae :~~azae or
separate days. In ol~e preferred embodiment of the present invention, the
active agents
are combined and administered in a single dosage form. In another preferred
embodiment, the active agents are administered in separate dosage forlnns
(e.g., wherein it
is desirable to vary the amount of one but not the other). The single dosage
form may
include additional active agents for the treatment of the disease state.
E I~PLES
The following e~~amples illustrates the lnventlon, but are clot limiting.
_74_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
EXAMPLE 1. Synthesis of Select Compounds In Formulation A(I)
General procedure A: Synthesis of 3-aryIoxycarbonyl-phenylboronic acid
HO~B~OH HO~g,OH
i
I \
off I ~ ci
02N O OZN HO~B~OH
O
,
O X
O~N t.R"
HO X R' O I ~ Z
(Ia) ~ Z R" (Ib)
step i, (COC1)2, DMF, CHZCIZ, rt, overnight
step ii, Et3N, CHZCl2, rt, overnight
In step (i) of general procedure A, oxalyl chloride (35 ~.L, 0.4 mmol) was
added to a suspension of (3-carboxyl-5-nitrophenyl)boronic acid (42 mg, 0.2
mmol), 1
drop of DMF and 5 mL of anhydrous CH2Clz. The reaction mixture was stirred at
room
temperature overnight and then evaporated to dryness to afford acid chloride
as a yellow
solid, which was used without further purification.
In step (ii) of general procedure A, a solution of the said chloride (0.2
mmol, obtained from step (i) above) in 5 mL of anhydrous CH2CI2 was added
dropwise
to an ice-cold solution of (Ia), anhydrous triethyl amine (42 ~,L, 0.3 mmol)
and 10 mL of
anhydrous CHzCIa. The reaction mixture was stirred at room temperature
overnight and
then evaporated to dryness. It was then dissolved in 25 mL of ethyl acetate
and washed
with 1N aqueous HCl, 10% aqueous NaHC~3, saturated brine solution, dried
(Na2S~4)
a~~d then comentrated. Tlm residLae uses pua-ified bay flash chr~n pat~graphy
eluting with
Me~H-ethyl acetate (1:10). The product yielded from step (ii) is (fth).
~orl~pound (la) (3-(4-Nitrophenoxycarbonyl)-5-nitrophenylboronic acid)
HO~~~OH
o w
OaN ~I
O v 'NOz
To make compound (1 a) p-Nitrophenol (21 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to yield 4~2 mg (~4~~/o yield) of
3-(4-
-75-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Nitrophenoxycarbonyl)-S-nitrophenylboronic acid as a white powder, mp: 205-
207°C.
1H-NMR(300MHz, d6-DMSO): 87.61-7.66 [m, 2H, Ar-H], 8.30-8.35 [m, 2H, Ar-H],
8.78-8.89 [m, 3H, Ar-III.
Compound (lb~ (3-(2-Nitrophenoxycarbonyl)-5-nitrophenylboronic acid)
HO~B~ON
\ NOa
/ o
O~N
O I /
To make the compound (lb) o-Nitrophenol (21 mg, 0.15 mmol) was
treated according to general procedure A, step (ii), to give 36 mg (72% yield)
of 3-(2-
Nitrophenoxycarbonyl)-5-nitrophenylboronic acid as a pale yellow powder, mp:
128-
130°C. 1H-NMR(300MHz, d6-DMS~): X7.52-7.7I [m, 2H, Ar-H], 7.81-7.94 [m,
IH,
Ar-H], 58.13-8.24 [m, IH, Ar-Hj, 8.70-8.93 [m, 3H, Ar-ICJ.
Compound (lc) (3-(3-Nitrophenoxycarbonyl)-5-nitrophenylboronic acid)
HO.B~OH
0 \ NOa
02N
To make compound (Ic), f~a-Nitrophenol (21 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 42 mg (82% yield) of 3-(3-
Nitrophenoxycarbonyl)-5-nitrophenylboronic acid as a light yellow crystal, mp:
185-
187°C. 1H-NMR(300MHz, d6-DMS~): b'7.72-7.81 [m, 2H, Ar-~l], X8.15-8.29
[m, 2H,
Ar-II], 8.76-8.89 [m, 3H, Ar-~1].
Compound 1 d) (3-(4.-l~~ethoxyphenoxycarbonyl)-5-nitrophenylboronic acid)
~~e~~ta~t
/ r~ \
oaN
I/
OCH3
To make compound (ld),p-Methoxyphenol (19 mg, 0.15 mmol) was
treated according to general procedure A, step (ii), to give 39 mg (81% yield)
of 3-(4-
Metho~yphenoxycarbonyl)-5-nitrophenylboronic acid as a white needle, mp:
67°C. 1H-
-76-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
NMR(300MHz, d6-DMS~): X3.74 [s, 3H, OCH3], 6.93-6.99 [m, 2H, Ar-HJ, 7.19-7.24
[m, 2H, Ar-H], 8.72-8.87 [m, 3H, Ar-H].
Comt~ound (le) (3-(4-Ethoxycarbonylphenoxycarbonyl)-S-nitrophenylboronic
acid)
HO,B,OH
o2N
0
COOCH2CH3
To make compound (le), ethyl 4-hydroxybenzoate (25 mg, 0.15 mmol)
was treated according to general procedure A, step (ii), to give 51 mg (94%
yield) of the
desired compound as a white powder, mp: 230-232°C. 1H-NMR(400MHz, d6-
DMSO): ~
1.31 [t, 2H, CH2CH3], 4.30 [q, 3H, CHZCHj], 7.50 [d, 2H, Ar-HJ, 8.05 [d, 2H,
Ar-H],
8.78-8.90 [m, 3H, Ar-H].
Compound elf) (3-(2-~xo-benzo[1,3]oxathiol-6-oxycarbonyl)-5-
nitrophenylboronic acid)
H~.~.~H
~2H
To make compound (lf), 6-Hydroxy-1,3-benzoxath iol-2-one (25 mg, 0.15
mmol) was treated according to general procedure A, step (ii), to give 50 mg
(92% yield)
of the desired compound as a white powder, mp: 145-14.7°C. 1H-
NMR(300MHz, d6-
DIVSG~: X7.28-7.36 [r~~~ 1Hg Aa--H], 7.56-7.64 [ray lI~g Ar-~l], 7.7~,-7.86
[m~ 1~T, Aa--H],
8.72-8.86 [m, 3H, Ar-H].
Compound (1~) (3-(2-Cyanophenoxycarbonyl)-5-nitrophenylb~ronic acid)
H~.Bs~H
GN
~r o
O~N
To make compound (lg), 2-Hydroxybenzonitrile (18 mg, 0.15 mmol) was
2~ treated according to general procedure A, step (ii), to give 4.3 mg (92%
yield) of the
_77_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
desired compound as a white powder, mp: 248-250°C. 1H-NMR(400MHz, d6-
DMSO): ~
7.48-7.57 [m, 1H, Ar-H], 7.62-7.69 [m, 1H, Ar-H], 7.78-7.89 [m, IH, Ar-KJ,
7.96-8.01
[m, 1H, Ar-H], 8.83-8.94 [m, 3H, Ar-H].
Compound (lh~ (3-(2-Chloro-6-nitrophenoxycarbonyl)-5-nitrophenylboronic acid)
NO~B~OH
NOZ
O
O~N
OCI
To make compound (lh), 2-Chloro-6-nitrophenol (26 mg, 0.15 mmol)
was treated according to general procedure A, step (ii), to give 39 mg (71%
yield) of the
desired compound as a yellow needle, mp: 179°C. rH-NMR(300MHz, d6-
DMSO): 8
7.54-7.72 [m, 1H, Ar-H], 8.01-8.24 [m, 2H, Ar-H], 8.65-8.94 [m, 3H, Ar-H].
Compound (1i) (3-(2-Ethoxycarbonyl-phenoxycarbonyl)-5-nitrophenylboronic
acid)
H~.~.OH
C~~CH2CH3
~i o
To make compound (li), ethyl salicylate (25 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 35 mg (64% yield) of the
desired
compound as a yellow semisolid. 1H-MVIR(300MHz, d6-DMSO): ~ 1.24 [t, 2H,
CfIZCH3], 4.31 [q, 3H, CH2CFI3J, 7.41-7.57 [m, 2H, Ar-I~, 7.81-8.05 [m, 2H, Ar-
I~'],
8.67-8.93 [m, 3~I, ~~a-~].
Compound (li) (3-(2-Chloropheno~,ycarbonyl)-S-nitrophenylboronic acid)
H~.~oOH
GI
~i o
~2N
O
To make compound (1j), o-Chlorophenol (19 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 4~4~ mg (90% yield) of
the desired
_7g_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
compound as a white powder, mp: 138-140°C. 1H-NMR(300MHz, d6-DMSO):
~7.38-
7.78 [m, 4H, Ar-H], 8.71-9.04 [m, 3H, Ar-H].
Compound (lk) (3-(2-Methylphenoxycarbonyl)-5-nitro-phenylboronic acid)
HO.B.OH
Me
O
02N
O
To make compound (lk), o-Cresol (16 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 40 mg (89% yield) of the
desired
compound as a yellow powder, mp: 175°C(dec). 1H-NMR(300MHz, d6-DMSO):
X2.17
[t, 3H, CH3], 7.21-7.40 [m, 3H, Ar-H], 8.15-8.22 [m, 1H, Ar-H], 8.65-8.91 [m,
3H, Ar-
H] .
Compound (11) (3-(2-Methoxylphenoxycarbonyl)-5-nitrophenylboronic acid)
HO.B.OH
OGH3
O~N
~ ~ i
To make compound (11), guaiacol (19 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 44 mg (92% yield) of the
desired
compound as a yellow semisolid. 1H-NMR(300MHz, d6-DMSO): X3.69[s, 3H, OCH3],
7.46-8.03 [m, 4H, Ar-H], 8.64-8.97 [m, 3H, Ar-H].
C~n1~~band (1n~) ~3-(3-T~ethylphen~~gyc~rbony~l)-6-~~itrophea~ylh~roa~c acid)
HO~~~OH
~~ \ CHs
~zN
To make compound (lm), na-Cresol (16 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 41 mg (91% yield) of the
desired
compound as a yellow semisolid. 1H-NMR(300MHz, d6-DMSO): 82.35 [t, 3H, CH3],
7.79-8.30 [m, 4~H, Ax-H], 8.71-8.91 [m, 3H, Ar-H].
-79-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Compound (ln) (3-(2,6-Dichlorophenoxycarbonyl)-5-nitrophenylboronic acid)
HO~B~OH
\ CI
~/ o \
o~N
oct /
To make compound (ln), 2,6-Dichlorophenol (25 mg, 0.15 mmol) was
treated according to general procedure A, step (ii), to give 43 mg (80% yield)
of the
desired compound as a pale yellow powder, mp: 167-169°C. 1H-NMR(300MHz,
d6-
DMSO): X7.39-7.44 [m, 1H, Ar-H~, 7.52-7.67 [m, 2H, Ar-H], 8.83 [t, 1H, Ar-HJ,
8.94-
8.96 [m, 2H, Ar-H].
Compound (lo) (3-(2-Fluorophenoxycarbonyl)-5-nitrophenylboronic acid)
H~~B,,OH
\ F
O \
OzN
O
To malce compound (10), 2-Fluorophenol (17 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 39 mg (85°/~
yield) of the desired
compound as a white needle, mp: 144-14.6°C. 1H-NMR (4~OOMH~, d6-DMS~+
DZ~): ~
7.29-7.53 [m, 4H, Ar-III, 8.80 [s, 1H, Ar-FI], 8.89-8.93 [m, 2H, Ar-H].
Compound (1p) (3-(2,6-Difluorophenoxycarbonyl)-5-nitrophenylboronic acid)
HO~B~OH
F
/
~~N
To make compound (1p), 2,6-Difluorophenol (20 mg, 0.15 n~rnol) vras
treated according to general procedure .~, step (ii), to gi~re 39 mg (81
°f° yield) of the
desired Go111p~llnd as a white powder, mp: I24~-126°C. iH-
I~TMR(4~OOMH~, d~-
DMSO+D2O): x'7.23-7.38 [m, 2H, Ar-FIJ, 7.38-7.4.8 [m, 1H, Ar-.t~J, 8.81 [s,
1H, Ar-H],
8.86-8.96 [m, 2H, Ar-H].
Compound (la) (3-(4-Fluorophenoxycarbonyl)-5-nitrophenylboronic acid)
-80-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
HO,B,OH
O2N / O
O ( / F
To make compound (lq), 4-Fluorophenol (17 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 41 mg (89% yield) of the
desired
compound as a white powder, mp: 233-235°C. 1H-NMR(400MHz, S%D20 in d6-
DMSO):
87.21-7.42 [m, 4H, Ar-H], 8.76 [s, 1H, Ar-H], 8.83-8.95 [m, 2H, Ar-H].
Compound (lr) (3-(4-pyridyloxycarbonyl)-5-nitro-phenylboronic acid)
HO,B.OH
O
O~N
O I iN
To malce compound (lr), 4-Pyridinol (14 mg, 0.15 rnmol) was treated
according to general procedure A, step (ii), to give 34 mg (79% yield) of
title compound
as a pale yellow powder, rnp: 165°C(dec). 1H-IVMR(400MHz, 5%DaO in d~-
DMSO): 8
7.43-7.50 [m, 1H, Ar-f~], 8.67-8.72 [m, 1H, Ar-.~l], 8.77-8.86 [m, 3H, Ar-I~],
8.86-8.97
[m, 1H, Ar_FI].
IS Compound (ls) (3-(2-Chloro-3-pyridyloxycarbonyl)-5-nitrophenylboronic acid)
HO,~.OH
GI
I / ~ ~N
02N
To make compound (ls), 2-Chloro-3-pyridinol (19 mg, 0.15 nanxol),v,~as
treated according to general procedure f-~, step (ii), to give 37 mg
(77°!~ yield) of the
desired compound as a white powder, mp: 14.6-148°C. 1H-1~(4.OO1~H~,
5°;°°DZ~ in dG-
DMSO): X7.57-7.63 [m, 1H, Ar-II], 8.05-8.09 [m, 1H, Ar-I~], 8.39-8.4.3 [rn,
1H, Ar-H],
8.81 [s, 1H, Ar-H], 8.89-8.94 [m, 2H, Ar-H].
Compound (1t) (3-Phenoxycarbonyl-5-nitrophenylboronic acid)
-81-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
HO,B"OH
I~ o
02N
o I i
To make compound (lt), phenol (14 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 39 mg (91 % yield) of the
desired
compownd as a white needle, mp: 139-141°C. IH-NMR(400MHz, 5%DZO in dg-
DMS~):
X7.28-7.34 [m, 3H, Ar-HJ, 7.44-7.51 [m, 2H, Ar-H], 8.78 [s, 1H, Ar-H], 8.86-
8.92 [m,
2H, Ar-H] .
Compound (lu) (3-(2-Bromophenoxycarbonyl)-5-nitro-phenylboronic acid)
HO.B,OH
Br
02N
O l i
To make compound (lu), 2-Bromophenol (26 mg, 0.15 mmol) was treated
according to general procedure A, step (ii), to give 49 mg (90% yield) of the
desired
compound as a pale yellow powder, mp: 128-130°C. 1H-NMR(400MHz,
5°/~DZ~ in d6-
DMS~): X7.26-7.35 [m, 1H, Ar-H], 7.47-7.56 [m, 2H, Ar-H], 7.76-7.81 [m, 1H, Ar-
I~],
8.83-8.94. [m, 3H, Ar-~I].
Compound (lv) (3-(3-Boronophenoxycarbonyl)-5-nitrophenylboronic acid)
HO~B~OH
~H
~~-~ Ø, :-~ B~OH
~2N
To make compound (I~r), 3-Hydro~~yphenylboronic acid (21 mg~ 0.15
m111o1) was treated according to general procedure A, step (ii), to gi~re 32
nag (64~% yield)
of the desired compound as a pale yellow powder, mp: 228-230°C. 1H-NMR
(400MH~,
5%D20 in d6-DMSO): 87.30-7.36 [m, 1H, Ar-H], 7.41-7.47 [m, 1H, Ar-H], 7.60-
7.63
[m, 1H, Ar-H], 7.68-7.73 [m, 1H, Ar-H], 8.76-8.79 [m, 1H, Ar-FI], 8.84-8.90
[m, 2H, Ar-
-82-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Comt~ound (lw~ (3-(2,4-Dichloro-6-vitro-phenoxycarbonyl)-5-nitro-
phenylboronic acid)
HO~B~OH
\ NO~
O \
02N
OCI / CI
To male compound (lw), 2,4-Dichloro-6-nitrophenol (80%) (39 mg, 0.15
mmol) was treated according to general procedure A, step (ii), to give 52 mg
(87% yield)
of the desired compound as a pale yellow powder, mp: 184-186°C. 1H-NMR
(400MHz,
5%D20 in d6-DMSO): 8.34-8.38 [m, 1H, Ar-H], 8.828.84 [m, 1H, Ar-H], 8.90-8.91
[m,
1H, Ar-H], 8.94-8.96 [m, 1H, Ar-H].
Compound (1x) (3-(2,4-Dichloro-6-vitro-phenoxycarbonyl)-5-nitro-
phenylboronic acid)
HO~B~OH CI~CI
/ O
O~~I
~ I /
CI
To make compound (lx), 5-Chloro-2-(2,4-dichlorophenoxy)phenol (43
mg, 0.15 mmol) was treated according to general procedure A, step (ii), to
give 51 mg
(71% yield) of the desired compound as a pale yellow powder, mp: 193°C.
1H-IVMl2
(400MH~, 5%DZ~ in d6-DMSO): c~ 6.61-6.94 [m, 3H, Ar-~l], 7.15-8.07 [m, 3H, Ar-
I~],
8.71-8.76 [m, 1H, Ar-~l], 8.84-8.89 [m, 1H, Ar-I~], 8.89-8.96 [m, 1H, Ar-Fl].
C~?lllp~llnd (1y (3-(2,4~,6-Trichlorophenoxycarbonyl)-5-vitro-phenylboronic
acid)
HO~~,OH
a CI
~i
OzH
°cl ~ cl
To malce compound (ly), 2,4,6-Trichlorophenol (30 mg, 0.15 mmol) was
treated according to general procedure A, step (ii), to give 45 mg (77% yield)
of the
desired compound as a white powder, mp: 217°C(dec). 1H-NMI~ (4~OOMH~,
5°/~D~,C in
d~-DMS~): &7.24 [s, 2H, Ar-H], 8.77-8.80 [m, 1H, Ar-H], 8.90-8.96 [m, 2H, Ar-
~I~.
-83-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
EXAMPLE 2. Synthesis of Select Compounds In Formulation A(II)
General procedure B: Synthesis of 3-borono-5-nitrobenzoic acid 1,4-
phenylene ester
HO.B.OH HO.B.OH
i
w
~ i OH
O~N OZN I i CI B(OH)z
O O
R
ii I i O
O~N ~ O
R _ O I i O w NOz
I
Ho I / (IIb) B(oH)z
OH
(IIa)
i, (COCI)2, DMF, CHZC12, rt, overnight
ii, BtgN, THF, rt, overnight
In step (i) of general procedure B, oxalyl chloride (35 p,L, 0.4 mmol) was
added to a suspension of (3-carboxyl-5-nitrophenyl)boronic acid (42 mg, 0.2
mmol), 1
drop of hI4~IF and 5 mL of anhydrous CHZC12 . The reaction mixture was stirred
at room
temperature overnight and then evaporated to dryness to afford acid chloride
as a yellow
solid, which was used without fiu-ther purification.
In step (ii) of general procedure B, a solution of the acid chloride (0.2
mmol, obtained above in step (i)) in 5 mL of anhydrous THF was added dropwise
to an
ice-cold solution of 0.075 mrnol of (IIa), anhydrous triethyl amine (4.2 p,L,
0.3 mmol)
and 10 mL of anhydrous THF. The reaction mixture was stirred at room
temperature
overnight and then evaporated to dryness. It was then dissolved in 25 mL of
ethyl acetate
an ~ ~~ashed ~jith 11~T aqu~o~s HCla 10~r'~ aq~co~~s hiaH~~~P
~at~~~°atc~l braoo ~~ah~t~on, dried
(I~Ta2S~4) and concentrated. 'The residue was recrystalli~cd from ethyl
acetate/hexane.
'The product yielded from step (ii) is (~llb).
Compound (2a) (3-Borono-5-nitroben~oic acid 1,4-phenylene ester)
NOZ
B(OH)~
-84-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
To make the compound (2a), hydroquinone (9 mg, 0.075 mmol) was
treated according to general procedure B, step (ii), to give 32 mg (86% yield)
of the
desired compound as a white powder, mp: 271-273°C. 1H-NMR(300MHz, d~-
DMSO+D20): 87.43 [s, 4H, Ar-H], 8.79 [t, 1H, Ar-H], 8.84 [t, IH, Ar-H], 8.86
[d, 1H,
Ar-H].
_Compound (2b) (3-Borono-5-nitrobenzoic acid 2-chloro-1,4-phenylene ester)
r~o~
)2
To make compound (2b), chlorohydroquinone (11 mg, 0.075 mmol) was
treated according to general procedure B, step (ii), to give 3I mg (78% yield)
of the
deisred compound as a white powder, mp: 264-266°C. 1H-NMR(300MHz, d~-
DMS~): 8
7.46-7.79 [m, 3H, Ar-II], 8.79 [d, 1H, Ar-H], 8.88-8.92 [m, 2H, Ar-TI].
Com ound 2c) (3-Borono-5-nitrobenzoic acid 2-chloro-1,4-phenylene ester)
To make compound (2c), tetrachlorohydroquinone (I9 mg, 0.075 mmol)
was treated according to general procedure B, step (ii), to give 33 mg
(~9°/~ yield) of the
desired compound as ~ white powder, mp: 252°C. 1H-(30011~IHz, d~-DMS~):
~
8.71-8.7~ [m, 2H, Ar-I~], 8.93-8.99 [m, 4~H, ~'~r-~].
Compound (2d1 (3-Borono-5-nitrobenzoic acid 2-chloro-1,4-phenylene ester)
-85-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
B(OH)2
O~N
N02
B(OH)~
To make compound (2d), t-butylhydroquinone (12 mg, 0.075 mmol) was
treated according to general procedure B, step (ii), to give 54 mg (65% yield)
of the
desired compound as a pale yellow powder, mp: 104°C(dec). 1H-
NMR(300MHz, d6-
DMSO): ~ 1.34[s, 9H, CH3], 7.02-7.27 [m, 3H, Ar-H], 8.79-8.83 [m, 2H, Ar-H],
8.86-
8.92 [m, 4H, Ar-H] .
EXAMPLE 3. Synthesis of Select Compounds In Formulation A(III)
General procedure C: Synthesis of 3-aryloxycarbonyl-phenylboronic acid
HO.B,OH HO.B.OH
i
w ~ w
OH ~ / CI
O~N OaN ~O.B.OH
O O
W R'
~r
O ~~ R,
R, ~ i Z
HO I ~~ R" O (IIIb)
(IIIa)
step i, (COCI)2, I)IVIF, CHZCIz, rt, overnight
step ii, Et3N, CH~CIZ, rt, overnight
In step (i) of general procedure C9 o~al~rl chloride (35 NFL, 0.4 mmol) was
added to a suspension of (3-carbol~yl-5-nitrophenyl)boronic acid (4~2 mg, 0.2
mmol), 1
drop of DMF° and 5 mL of anhydrous CH~C12. The reaction mixture was
stirred at room
temperature overnight and then evaporated to dryness to afford acid chloride
as a yellow
solid, which was used without further purification.
In step (ii) of general procedure C, a solution of the acid chloride (0.2
mmol, obtained from step (i) above) in 5 mL of anhydrous CH2C12 was added
dropwise
to an ice-cold solution of (IIIa), anhydrous triethyl amine (42 ~.L, 0.3 mmol)
and 10 mL
of anhydrous CH2C12. The reaction mi~cture was stirred at room temperature
overnight
and then evaporated to dryness. It was then dissolved in 25 mL of ethyl
acetate and
-86-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
washed with 1N aqueous HCl, 10% aqueous NaHC03, saturated brine solution,
dried
(Na2S04) and then concentrated. The residue was purified by flash
chromatography
eluting with MeOH-ethyl acetate (1:10). The product yielded from step (ii) is
(IIIb).
Com ound 3a) (3-(2,6-Dichlorobenzyloxycarbonyl)-5-nitrophenylboronic)
HO,B~OH
CI
O
O~N
O CI
To make compound (3a), 2,6-Dichlorobenzyl alcohol (27 mg, 0.15 mmol)
was treated according to general procedure C, step (ii), to give 49 mg (89%
yield) of the
desired compound as a pale yellow semisolid. 1H-NMR(400MHz, 5%D20 in d6-DMSO):
X5.62 [s, 2H, Ar-CHZ], 7.26-7.62 [m, 3H, Ar-H], 8.57-8.95 [m, 3H, Ar-H].
Compound (3b) (3-(3-Nitrobenzyloxycarbonyl)-5-nitrophenylboronic acid)
HO~B~OH No
2
0
O2N jf
0
To make compound (3b), 3-Nitrobenzyl alcohol (23 mg, 0.15 mmol) was
treated according to general procedure C, step (ii), to give 43 mg (82% yield)
of the
desired compound as a pale yellow powder, mp: 14.2-144°C. 1H-NMR
(400MHz,
5°/~D20 in d6-DMSO): X5.46 [s, 2H, hr-CHz], 7.65-7.70 [m, 1H, l~r-H~,
7.93-7.97 [m,
1H, ~.r-IIJ, 8.09-8.12 [m, 1H, ~1r-H], 8.17-8.21 [m, 1H, ~1r-H], 8.62-8.94 [m,
3H, Ar-H].
Coanpound f3c) (3-(3-Chlorobenzylo~~y carbonyl)-5-nitrophenylboronic acid)
Ho.~~oH of
0
~aN
0
To make compound (3c), 3-Chlorobenzyl alcohol (22 mg, 0.15 mmol)
was treated according to general procedure C, step (ii), to give 44 mg (88%
yield) of the
desired compound as a white powder, mp: 91°C{dec). 1H-NMR(400MHz,
5°/~Da0 in d6-
DMSO): c~5.4.1 [s, 2H, ~r-CFI], 7.41-7.61 [m, 4~H, ~r-I~, 8.62-8.95 [m, 3H, Ar-
~I].
_87_
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Compound (3d) (3-(3-Boronobenzyloxycarbonyl)-5-nitrophenylboronic acid)
HO.B.OH HO.B.OH
\ i
r O
O2N
O
To make compound (3d), 3-Hydroxymethylphenylboronic acid (23 mg,
0.15 mmol) was treated according to general procedure C, step (ii), to give 35
mg (68%
yield) of the desired compound as a yellow semisolid. 1H-NMR (400MHz, 5%DZO in
d6-
DMSO): 85.39 [s, 2H, Ar-CHz], 7.27-7.84 [m, 4H, Ar-I~, 8.79-8.90 [m, 3H, Ar-
HJ.
Compound 3e) (3-(1-Naphthalenemethoxycarbonyl)-5-nitrophenylboronic acid)
HO~B~OH
\ /
/ O \
02N
to ° \
To male compound (3e), 1-Naphthalenemethanol (24 mg, 0.15 mmol)
was treated according to general procedure C, step (ii), to give 31 mg
(59°/~ yield) of the
desired compound as a yellow semisolid. 1H-NMR (300MHz, 5°f°Da0
in d6-DMSO): c~
s, , -CHZ], 7.5~- . m, , Ar-H]9 8.601- .87 [m, 3H, I~-H].
Compound (3f,~ (3-(3-Boronobenzyloxycarbonyl)-5-a~ninophenylboronic acid)
HO~~~OH HO~~~OH
\ /
O \
H2N
O
To make the compound (3fj, a solution of 3-(3-boronobenzyloacycarbonyl)
-5-nitrophenylboronic acid (172 mg, 0.5 mmol) in absolute ethanol (10 ml) was
20 hydrogenated in the presence of Raney Nielcel (80 mg) for 4 hours. The
catalyst was
removed by filtration and the solvent was evaporated to dryness, then the
residue was
recrystallized from ethanol/H~O to give 60 mg (38% yield) of the desired
compound as a
pale yellow semisolid. 1H-NMR(300MHz, 5%D~O in d6-1~MS0): ~ 5.25 [s, 2H, Ar-
CHZ],
6.56-6.97 [m, 2H, ~~.r-H], 7.15-8.09 [m, ~H, Ar-ICJ.
_88-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Compound (3~1 (3-(3-Boronobenzyloxycarbonyl)-5-hydroxylphenylboronic acid)
HO~B~OH HO~B~OH
\ /
/ O \
HO
O
To make the compound (3g), 3-(3-boronobenzyloxycarbonyl)-5-
aminophenylboronic acid (31 mg, 0.1 mmol) was suspended in 2 mL of 50% H2S04
and
treated at -5 °C with a solution of NaN02 (8 mg, 0.1 mmol) in 1 mL of
water. After the
mixture had been stirred for 1 h at this temperature, water (10 mL) was added
and the
mixture was warmed to 60 °C until the evolution of gas ceased. The dark
brown solution
was extracted twice with ethyl acetate, and the extracts were washed with
water and
brine and dried with Na2S04. The solvent was evaporated to dryness, then the
residue
was recrystallized from methanol to give 10 mg (32% yield) of the desired
compound as
a pale yellow powder, mp: 217°C(dec). 1H-NMIh(300MHz, 5%D2O in d6-
DMSO): ~
5.39 [s, 2H, Ar-CHz], 7.07-7.64 [m, 3H, Ar-H], 7.89-8.27 [m, 4H, Ar-H].
~~aAH~LE 4. ~ynthe~a~ ~f 'elect COarip~unc~s In ~"~ra~aulati0n A(~~
Compound (4.a) 3-(2-Fluorobenzamido)-5-caxboxylphenylboronic acid
HO,B,OH
O F
HOOD
To make compound (4a), 2-fluorobenzoyl chloride (60~,L,, 0.5 n~nnol) was
added dropwise over a period of 30 min to an ice-cold solution of 3-amino-5-
carboxylphenylboron is acid (91 mg, 0.5 mmol) and NaHCO3 (105 mg, 1.25 m111o1)
in 10
mL of water. The reaction mixture was Icept at 0°C for lh and then
stirred at room
temperature overnight. It was then extracted twice with 10 mL of ethyl ether.
The
aqueous solution was acidified with 1N aqueous HCl and extracted twice with 10
mL of
ethyl acetate. The combined organic layers were washed with water and
saturated brine
sohbtion, dried (Na2SOq.) and concentrated. The residue was recrystallized
from ethyl
-89-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
acetate/hexane to give 94 mg (62% yield) of the desired compound as a white
powder,
mp: 224-225°C. 1H-NMR(300MHz, 5%DZO in d6-DMSO): 57.21-7.38 [m, 2H, Ar-
H],
7.48-7.72 [m, 2H, Ar-H], 8.12-8.33 [m, 3H, Ar-I~.
E~~AMPLE 5. Synthesis of Select Compounds In Formulation A(XI)
Com~oun~5a) (3-amino-5-carboxylphenylboronic acid)
HO~B,ON
HOOD ~ NH2
To make the compound (Sa), a solution of 3-carboxyl-5-
nitrophenylboronic acid (422 mg, 2 lxnnol) in absolute ethanol (5 ml) was
hydrogenated
in the presence of Raney Nickel (150 mg) for 6 hours. The catalyst was removed
by
filtration and the solvent was evaporated to dryness, then the residue was
recrystallized
from water to give 257 mg (71 % yield) of the desired compound as a pale
yellow powder,
mp: 2I0-212°C (Ref. mp: 212-214.°C). 1H-NMR(400MHz, 5%DZO in d6-
DMSO): X7.06
[s, 1H, Ar-H], 7.16 [s, 1H, Ar-~IJ, 7.55 [s, 1H, ~,r-H] (Torssell, I~.; Meyer,
H.; Zacharias,
~. ~(~kiv I~enai 1957,10, 497-505).
E~~PLE 6. Synthesis of Select i~'.orelpounds In Formulation A(I)
Compound (6a) (3-(2, 6-Dichlorophenylcarbonyloxy)phenyl boronie acid)
H~~~,,OH
O CI
OeC
Cf
To make compound (6a), a solution of 2,6-dichlorobenzoyl chloride (29
~,L, 0.2 mmol) in 5 rnL of dried THF was added dropwise to an ice-cold
solution of 3-
hydroxyphenylboronic acid (21 mg, 0.15 mmol), dried triethyl amine (42 ~.L,
0.3 mmol)
and 10 mL of dried THF. The reaction mixture was stirred at room temperature
overnight
and then evaporated to dryness. It was dissolved in 2S mL of ethyl acetate and
washed
with 1N aqueous HCI, 10% aqueous NaHCO3, saturated brine solution, dried
(NaaS04)
-90-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
and then concentrated. The residue was purified by flash chromatography
eluting with
MeOH-ethyl acetate (1:10) to give 38 mg (81% yield) of desired compound as a
white
powder, mp: 238°C(dec). 1H-NMR (400MHz, 5%DaO in d6-DMSO): 87.08-7.19
[m, 1H,
Ar-H], 7.22-7.30 [m, 1H, Ar-H], 7.22-7.30 [m, 1H, Ar-H], 7.42-7.50 [m, 1H, Ar-
H],
7.54-7.60 [m, 1H, Ar-H], 7.60-7.68 [m, 2H, Ar-H], 7.73-7.78 [m, 3H, Ar-H].
E~~AMPLE 7. Synthesis of Select Compounds In Formulation A(XIII)
Compound (7a) 4-Borono-2-fluorobenzoic acid 2-chloro-1,4-phenylene ester
HO~B~ON OH
\ / I B~OH
F / / O \
O O \ I O F
W step (i), oxalyl chloride (35 ~.L, 0.4 mmol) was added to a suspension
of 3-fluoro-4-carboxylphenylboronic acid (37 mg, 0.2 mmol), 1 drop of DMF and
5 mL
of dried CH2C12. The reaction mixture was stirred at room temperature
overnight and
then evaporated to dryness to afford acid chloride as a yellow solid, which
was used
without further purification in step (ii).
In step (ii), a suspension of the above acid chloride (0.2 rninol, obtained
from step (ii)) in 5 mL of dried THF was added dropwise to an ice-cold
solution of
chlorohydroquinone (11 mg, 0.075 mmol), anhydrous triethyl amine (4~2 ~L, 0.3
mmol)
and 10 mL of anhydrous THF. The reaction mixture was stirred at room
temperature
overnight and then evaporated to dryness. It was dissolved in 25 mL of ethyl
acetate and
~r~~l' eel vrith 11~T aqueous HC'h 10°f~ aqne~a~~s i'J~HCO~~
sat~.~r~ated brine solutior~9 dried
(lVa2SO4) and then concentrated. The residue was purified by flash
chromatography
eluting v~ith MeOH-ethyl acetate (1:10) to give 26 mg (74.% yield) of the
desired
compound as a pale yellow povJder, mp: 228-230°C. 1H-1~TMR (400~,rH~,
5°/~I~20 in d6_
DMSO): &6.52-6.55 [m, 1H, Ar-FI], 6.68-6.76 [m, 2H, ~1r-FIJ, 6.94-7.06 [m, 1H,
Ar-11],
7.21-7.34 [m, 1H, Ar-H], 7.57-7.78 [m, 3H, Ar-H], 7.99-8.11 [m, 1H, Ar-H].
E MPLE 8. Synthesis of Select Compounds In Formulation A(~IV)
-91-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Compound 8(a) (4-(2-Chloro-6-nitrophenoxycarbonyl)-3-fluorophenylboronic
acid)
O2N
HO
B
HO O CI
F
In step (i), oxalyl chloride (35 ~,L, 0.4 mmol) was added to a suspension
of 3-fluoro-4-carboxylphenylboronic acid (37 mg, 0.2 mmol), 1 drop of DMF and
5 mL
of dried CH2Clz. The reaction mixture was stirred at room temperature
overnight and
then evaporated to dryness to afford acid chloride as a yellow solid, which
was used
without further purification in step (ii).
In step (ii), a suspension of the above acid chloride (0.2 mmol) in 5 mL of
dried THF was added dropwise to an ice-cold solution of 2-chloro-6-nitrophenol
(26 mg,
0.15 mmol), dried triethyl amine (42 ~.L, 0.3 mmol) and 10 mL of dried THF.
The
reaction mixture was stirred at room temperature overnight and then evaporated
to
dryness. It was dissolved in 25 mL of ethyl acetate and washed with 1N aqueous
HCI,
10% aqueous NaHC~3, saturated brine solution, dried (Na2SC~) and concentrated.
The
IS residue was purified by flash chromatography eluting with Me~H-ethyl
acetate (1:10) to
give 40 mg (79% yield) of the desired compound as a pale yellow powder, mp:
174-
175°C. IH-NMR (400MHz, 5°/~DZ~ in d6-DMS~): 87.61-7.36 [m, 1H,
Ar-H], 7.7I-7.74
[m, 1H, f1r-HJ, 7.77-7.79 [m, 1H, Ar-II], 8.07-8.11 [m, 2H, Ear-FIJ, 8.I8-8.21
[m, 2H, Ar-
~IJ.
~~~AL~FaL~ 9. ~ynt:Ig~~n~ ~f ~ele~t c~~a~p~~n~ad~ ~n h"~~w~aLata~n A(~~
Compound (9a) (3-l3orono-5-nitroben~oic acid I,3-phenylene ester)
HO'e~OH HO\geOH
O2N I .~ O I \ O \ I NO~
O ~ O
In step (i), oxalyl chloride (35 ~,L, 0.4 mmol) was added to a suspension
of 3-carboxyl-5-nitrophenylboronic acid (42 mg, 0.2 mmol), 1 drop of DMF and 5
mL of
dried CHZC12. The reaction mixture was stirred at room temperature overnight
and then
-92-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
evaporated to dryness to afford acid chloride as a yellow solid, which was
used without
further purification in step (ii).
In step (ii), a solution of the above acid chloride (0.2 mmol) in 5 mL of
dried THF was added dropwise to an ice-cold solution of resorcinol (9 mg,
0.075 mmol),
dried triethyl amine (42 ~.L, 0.3 mmol) and 10 mL of dried THF. The reaction
mixture
was stirred at room temperature overnight and then evaporated to dryness. It
was
dissolved in 25 mL of ethyl acetate and washed with 1N aqueous HCI, 10%
aqueous
NaHC03, saturated brine solution, dried (NaZS04) and concentrated. The residue
was
purified by flash chromatography eluting with MeOH-ethyl acetate (1:10) to
give 26 mg
(70% yield) of the desired compound as a pale yellow powder, mp:
134°C(dec). 1H-
NMR (400MHz, 5%D2O in d6-DMSO): eS6.14-6.18 [m, 2H, Ar-H], 7.33-7.45 [m, 2H,
Ar-H], 8.75-8.82 [m, 2H, Ar-H], 8.85-8.90 [m, 4H, Ar-HJ.
EXAMPLE 10. Synthesis of Select Compounds In Formulation A(XVI)
Compound (l0a) (3-Borono-S-nitrobenzoic acid 1,2-benzenedimethanol ester)
oy
In step (i), oxalyl chloride (35 p.L, 0.4 mmol) was added to a suspension
of (3-carboxyl-5-nitrophenyl)boronic acid (42 mg, 0.2 mmol), 1 drop of DMF and
S mL
of driel CH~~'lf, The reacti~an mid~ture ~~~s stirred at room ten ~pex~ture
overnight and then
evaporated to dryness to afford acid chloride as a yellow solid, which was
used v~ithout
further purification in step (ii).
In step (ii), a suspension of the above acid chloride (0.2 mrnol, obtained
from step (ii)) in 5 mL of dried THF was added dropwise to an ice-cold
solution of 1,2-
benzenedimethanol (10 mg, 0.075 mmol), anhydrous triethyl amine (42 q,L, 0.3
mmol)
and 10 mL of anhydrous THF. The reaction mixture was stirred at room
temperature
overnight and then evaporated to dryness. It was dissolved in 25 mL of ethyl
acetate and
washed urith 1N aqueous HCI, 10% aqueous NaHCO3, saturated brine solution,
dried
(Na2SO4) and then concentrated. The residue was purif ed by flash
chromatography
-93-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
eluting with MeOH-ethyl acetate (1:10) to give 21 mg (53% yield) of the
desired
compound as a pale yellow powder, mp: 142°C(dec). 1H-NMR (400MHz,
5%D~,O in d6-
DMSO): 85.64 [s, 4H, CHZ], 6.14-6.18 [m, 2H, Ar-H], 7.33-7.45 [m, 2H, Ar-H],
8.77-
8.84 [m, 2H, Ar-H], 8.87-8.93 [m, 4H, Ar-FIJ.
EXAMPLE 11. Synthesis of Select Compounds In Formulation A(XVII)
Compound (11a) (1,4-Benzenedicarboxylic acid, di 3-boronophenyl ester)
To make compound (12a), a solution of terephthaloyl chloride (2lmg, 0.1
mmol) in 5 mL of dried THF was added dropwise to an ice-cold solution of 3-
hydroxyphenylboronic acid (21 mg, 0.15 nunol), dried triethyl amine (28 ~,L,
0.2 mmol)
and 10 mL of dried THF. The reaction mixture was stirred at room temperature
overnight
and then evaporated to dryness. It was dissolved in 25 mL of ethyl acetate and
washed
with lIV aqueous HCI, 10% aqueous lZTaHCO3, saturated brine solution, dried
(NazSO4)
and then concentrated. The residue was purified by flash chromatography
eluting with
MeOH-ethyl acetate (1:10) to give 16 mg (51% yield) of the desired compound as
a
white powder, mp: 214°C(dec). 1H-NMR (400MHz, 5%DZO in d6-DMSO): ~ 7.28-
7.34
[m; 2H, hr-H], 7.38-7.46 [m, 2H, Ar-~IJ, 7.59-7.63 [m, 2H, I~rr-H], 7.68-7.73
[m, 2H, Ar-
~1], 8.30 [s, 4H, Ar-I~].
E~'~IVrY~II~J~ 12. ~ynthe~is of select ~~~ggpo~nr~ds In F'or~~ulatn~n
~(~~~I(I~I)
Compound 12a~ (Tris(3-borono-5-nitrobenzoic acid), 1,3,x-trihydroxybenzene
ester)
-94-
H~ nN
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
B(OH)a B(OH)~
/ NOz
O
NO2
In step (i), oxalyl chloride (79 ~,L, 0.9 mmol) was added to a suspension
of (3-carboxyl-5-nitrophenyl)boronic acid (95 mg, 0.45 mmol), 1 drop of DMF
and 10
mL of dried CH2Cl2, The reaction mixture was stirred at room temperature
overnight
and then evaporated to dryness to afford acid chloride as a yellow solid,
which was used
without further purification in step (ii).
In step (ii), a suspension of the above acid chloride (0.2 mmol, obtained
from step (ii)) in 5 mL of dried THF was added dropwise to an ice-cold
solution of
phloroglucinol (13 mg, 0.1 mmol), anhydrous triethyl amine (42 p.L, 0.3 mmol)
and 10
mL of anhydrous THF. The reaction mixture was stirred at room temperature
overnight
and then evaporated to dryness. It was dissolved in 25 mL of ethyl acetate and
washed
with lIV aqueous HCI, 10% aqueous lVaHC~3, saturated brine solution, dried
(IVaZS~4)
and then concentrated. The residue was purified by flash cluomatography
eluting with
MeOH-ethyl acetate (1:10) to give 17 mg (24% yield) of the desired compound as
a pale
yellow powder, mp: 274°C(dec). 1H-Nl~ (400MHz, 5%D20 in d6-DMS~): X7.46
[s,
1H, Ar-II], 8.72-x.76 [m, 1H, ~r-I~J, ~.7~-~.~6 [m, 2H, Ar-I~.
%~~~1~~ L~ g3. Tlr~l~abn~:i0~a /~~~~~
The inhibition ofTEM-1 ~-lactamase ,vas determined
spectrophotometrically. E-lactamase activity urea followed by measuring the
hydrolysis
of nitrocefin, [3-(2,4-dinitrostyryl)-(6I~, 7I~)-7-(2-thienylaeetamido)-ceph-3-
ean-4-
carboxylic acid, E-isomer], (Calbiochem, San Diego, CA, USA) at 486 nm.
Inhibition
assays were performed at 25°C in 50 mM sodium phosphate, 5 % DMSO, pH
7Ø The
enzyme concentration was held at SmM, with substrate at 167 ~,M and varying
inhibitor
concentrations. Inhibitor was added to the enzyme and incubated for ten
minutes before
the addition of substrate. Inhibition constants (I~;) for the inhibitors are
obtained at the
-95-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
desired temperature and solvent conditions by measuring the rate of substrate
hydrolysis
at increasing amounts of inhibitors.
Table 11 shows the ~3-lactamase inhibition data of the compounds of the
present invention obtained using inhibition assay described above. The Iii
values in the
parenthesis obtained from a Lineweaver-Burke analysis.
Table 11 Results of TEM-1 ~8-Lactamase Inhibition Assay
~(N~M)
Compound (~ from Lineweaver-
Burke Analysis)
(la) 809
123
(1b)
(1.18)
(lc) 397
1 d) 427
( 1 e) >1000
(1 ~ 334
373
(lg) (I.37)
9.50.8
(lh)
(0.65)
(li) 1014
282
(1~) (1.31)
(llb) 13018
(11) 1167
(1m) 11~~~12
(2a) 22.7 1.3
(2b) 15.2 1.4
8.80.5
(ln)
(0.62)
(1~) 49.34.6
(lp) 19.81.3
-96-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
(4a) 1439
( 1 q) 1008
342.9
(3 a)
(4.97)
(lr) 1382.7
(5a) 72749
( 1 s) 42.32.4
958.7
(lt)
(6.54)
273.4
(3b)
(2.76)
251.5
(3c)
(2.35)
252.5
(lu)
(1.68)
(6a) 282.1
(lv) 321.1
(3d) 55.74..3
(7a) 12210
(8a) 431.6
(9a) 161.5
(lw) 131.1
F1001 104
F1002 14.8
F1012 113
F1201 27
F1212 95
BB-1003 231
BB-1004 297
BB-1005 392
~~1 F~I~E 1~~. Baaadi~~ 'i~~r~~tg~s ~~~r~~ib~~~~~
-97-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
The binding of the compounds of the present invention to (3-lactamase
was also measured by isothermal titration calorimetry. Isothermal titration
calorimetry
does not only measure the binding affinity of inhibitors but also dissects the
enthalpic
and entropic components to binding, thus allowing identification of the forces
involved
in the association reaction. In general a binding reaction characterized by a
favorable
enthalpy change indicates that the inhibitor establishes strong interactions
with the target,
whereas an inhibitor characterized by unfavorable binding enthalpy is driven
by non-
specific hydrophobic interactions, i.e., a tendency to escape water rather
than a strong
attraction to the target (Velazquez-Campoy et al., (2001) Arch. Bioclum.
Biophys. 390,
169-I75; and Ohtal~a et al., (2002) Protein Science 11, 1908-I9I6).
Table 12. Binding Enthalpy of Selected Compounds
~H wt ~H M69I OH E104I~ ~H R244S
Compound
cal/mol cal/mol cal/mol cal/rnol
(Ib) -3800 -2000 -3900 -9500
F1201 -3200 -2400 -3500 -6500
F1212 -4700 -3300 -4500 -8900
(lh) -1140 -953 -1896 -11931
(lj) -214.5 -1693 -2756 -6877
(1g) -5520 -2460 -6397 -8200
These experiments, in combination with the inhibition assays, indicate
that the compounds identified in this disclosure bind to the wild type as well
as drug
resistant beta lactaimases v~ith favorable binding enthalpies. This is a very
in~porLant
characteristic from the point of view of further optimization since it
facilitates the
achievement of extremely high affinities and low susceptibilities to dung
resistant
lnutations and naturally occurring polymorphisms.
EXAMPLE 15. Activity Against Clavulanic Acid Resistant Mutants
As discussed above, the use of (3-lactam-based ~3-lactamase inhibitors has
led to the appearance of infectious microorganisms that carry mutated versions
of the
beta lact~mase enzyme that are not efficiently inhibited by beta lactamase
inhibitors
-98-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
currently in clinical use (clavulanic acid, sulbactam, tazobactam) (Bonomo et
al, 1997).
Three of the most important mutations are M69I, R244S and E104K. The mutations
M69I and R244S significantly lower the affinity of clinically used beta
lactamase
inhibitors whereas the mutation E104K does not have a direct effect on the
affinity of
those molecules but increases the hydrolysis rates of extended spectrum
antibiotics.
Compounds of the present invention were tested against these mutations as
sho~xm in
Table 13. As shown in Table 13, while the existing clinical inhibitors lose
potency
between one to over two orders of magnitude, compounds of the present
invention
maintain equivalent potency against wild type and drug resistant mutants, and
in many
I O cases exhibit better potency against drug resistant mutants.
Table 13. Loss of Potency Against ~3-Lactamase Mutants Expressed as
the Ratio of the Inhibitory Constant Between Mutant and Wild Type
(PQtenCy~,t~PotBnCyt"utant~~ °~
Compound M69I R244S E104K
Clavulanic 163 38 0.67
Sulbaetam 15 93 1
Tazobactam 31 1 OS 1
(lh) 1.2 0.86 0.77
(lb) 1.0 1.2 0.92
F1201 0.52 0.86 0.48
(lj) 0.33 0.37 0.15
(1f) 0.47 0.42 0.37
(lg) 0.4.0 0.26 0.32
(1d) 0.60 0.62 0.55
(lc) 1.0 0.52 0.~6
(1 a) 0.43 0.44. 0.39
(li) 0.50 0.34. 0.36
*A number higher than 1 reflects a loss of potency against mutant
E~~aanpic 16 Rccovcry of Antibiotic Potency in Antibacterial Assay
The following four compounds
-99-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
HO~B~OH
\ r
O
O~N
(compound F1201);
HO~B.OH
r o\
O~N
O (compuond F1202);
HO~B~OH
r OH
o (compound F1203); and
Ho~B~OH
\ N02
0
O~N
o I ~ (compound F1204)
were tested against three different strains:
(1) methicillin resistant ~S. aur~eus ATCC 33591 (MRSI~-ATCC).
This strain was obtained from American Type Culture Collection (ATCC),
Mantissas,
~9
(2) methicillin resistant S. azc~eazs from Stanford University 1-iospital
Clinical Microbiology/Virology Laboratory (MI~S~-Sue. This strain was isolated
from
a blood culture and was found to be resistant to nafeillin and o~acillin. Such
Staplzylococci are also resistant to all penicillins, and all cephalosporins,
in addition to all
,~-Iactamase inhibitor combinations (including a~lxlpicillin/sulbactarl,
amo~icillin/cla~~.alanic acid, piperacillil~/ta~~obactsm), 11111p~11~I11, and
n~leropemla~; ~~d
(3) lnethicillin sensiti~re ~: arii~c~cs ~.TCC 25923 (MSS). This strain
was obtained from ATCC and ~rras used as a control.
~~acillin (Lot # 11~I~104~1) was purchased from Sigma Chemical
Company, St. Louis, M~.
EXPERIMENTAL PROCED URES
~ultivatioaz afa.d Maiaa.tc~~aazce of Test ~y~ga3zisfyas
-100-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
The strains were processed according to procedures recommended by
ATCC, or procedures that are routinely used. Single colonies of each organism
were
picked for purification to generate pure working cultures. Prior to each
experiment each
strain was subcultured on a fresh Mueller-Hinton agar plate (MHA).
Ifaoculuua
Inocula for the MIC assays were prepared by transferring a tiny portion of
one colony from a MHA plate to 2 ml of Mueller-Hinton broth (MHB) such that
the
estimated cell density was about 10' colony forming unit (CFU)/ml. This cell
suspension
was then further diluted 10-fold (to 106 CFU/ml) by transferring the 2 ml cell
suspension
to 18 ml of MHB. Addition of SO ~,1 of this dilute cell suspension to 50 ~ul
of growth
medium yielded the desired cell density, namely about 5 x 104 CFU/well, or S x
105
CFU/ml.
Br~t12 lVlicf°odilutioh Ps oceduy°e
The MIC value of oxacillin was determined using the broth microdilution
procedure recommended by the National Committee of Clinical Laboratory
Standaxds
(NCCLS, 2000). This procedure was also used to determine whether any of the
inhibitors
exhibited antimicrobial activity.
~~IICAssays with ~xczcillirr.
The MIC experiments were performed in duplicate in 96-well microtiter
plates using MHB. A stoclc solution of 2.6 mg/0.5 ml was prepared in
dimethylsulfoxide (DMS~). A total of 8 two-fold serial dilutions were made
with
~1~~~. Initial o~~a~;illin doses used were (~,ghnl)e 6~., 32, 16, 8~ ~, 2, 19
an~~ Oo~. Doses
were adjusted in the confirmatory experiment, if needed, in order to establish
an actual
MIC ~ralue.
To each well of a 96 well microtiter plate was added 4.7.5 ~,1 of MHB. A
volume of 2.5 ,ul of each dilution of oxacillin was then transferred to
appropriate wells
containing the medium. All wells, except the sterility control wells, were
then inoculated
with 50 ~.1 of a diluted cell suspension to give a anal volume of 100 ltl and
a final cell
density of 5 x 104' CFU/well. The volume in the sterility control wells was
adjusted to
100 ~.l with MHB. A sterile pipette tip was used to mix the contents of each
well (one tip
was used going from the low to the high concentration in the same column). The
-101-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
microtiter plates were covered with the lids and were placed in large
Stratagene Big Blue
plates (Cat. # 400041). Four large kimwipes moistened with tap water were
placed near
the edges of the Stratagene plates to prevent evaporation of the medium. The
microtiter
plates were incubated for at Ieast 24 hours at 35°C. The plates were
then evaluated for
growth in each well. Controls included: medium sterility and negative control
(medium
and bacteria only).
MIC Assays with Compouyads of the P~°esent Invehtiof2
The procedure used to determine the antimicrobial activity of the
compounds of the present invention was identical to the broth microdilution
procedure
described above with the exception of the preparation of the stock solutions.
Stock
solution at concentration of 40.96 mg/0.5 ml was prepared in DMSO for each of
the
compounds. A total of 8 two-fold dilutions were then made in DMSO. A volume of
2.5
~Cl of each dilution was delivered to appropriate wells. The initial doses
used were
(~,glml): 512, 256, 128, 64, 32, 16, 8, and 4.
Criteria fog MIC clctea~ynination
A numerical code was used to evaluate the extent of growth as indicated
below.
0: absence of growth
1: barely visible (faint) growth
2: fair growth but less than the negative solvent control
3: growth is equivalent to the negative solvent control.
The lowest dose at which no visible growth is observed was detenr~ined to
be the MIC' ~ralue.
Il~lc~ta°i.~: ~'hstetaa
The effect of the four compounds of the present in~rention on oxacillin
resistance of the MI~SA strains was determined using a matrix system. The ~3-
lactamase
inhibitors were tested at 5 doses against up to eleven concentrations of
oxacillin. The
highest dose of oxacillin and inhibitors used were at least one dose above the
MIC value,
with the exception of compound FL203 which was tested at a high dose of 512
~,l/ml
which was not bacterioto~ic to an y of the strains used. A 96-well microtiter
plate was
used for the matrix system. The procedure was identical to that described
above for the
-102-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
MIC determination, with the exception that both oxacillin and one each of the
(3-
lactamase inhibitors was added, 2.5 ~,1 each, to the wells prior to addition
of the test
organisms.
RESULTS AND DISCUSSION
MIC Evaluation of Oxacillih and tlae Fouy~ Cofnpounds
MIC assays were performed with oxacillin and the four compounds. Each
of the compounds was tested at the following 8 doses (~g/ml): 512, 256, 128,
64, 32, 16,
8, and 4. Oxacillin was tested at the following 8 doses (~.g/ml): 64, 32, 16,
8, 4, 2, 1, and
0.5. The MIC values obtained were tabulated in Table 14. These MIC data
indicate that
these four compounds have antibacterial activities.
Table 14
Test Compound Compound Compound Compound
~a;acillin
~rganism F1201 F1202 F1203 F1204
MRSt~-
32 16 > 512 256 32
ATCC
MSSA 32 128 > 512 512 0.25
MI~SA-SU 32 256 >512 512 > 64
lvlat~ix Study: Oxacillin and Cofnpoasnd FL201 yvith MRSA-ATCC
The results are shown in Table I5.
T'abl~ l~s
Cotn~ottnd FI?~l
Oxa.cillin
~.g/ml 0 16 l~ 4 2 1
0 3 0 1 2 3 3
64 0 0 0 0 0 0
32 2 0 0 0 0 0
16 2 0 0 0 0 0
-103-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
8 3 0 0 0 0 1
4 3 0 0 0 0 I
2 3 0 0 0 0 1
1 3 0 0 0 1 I
0.5 3 0 0 0 1 1
0.25 3 0 0 1 I 1
0.125 3 0 0 1 1 1
0.064 3 0 0 I 1 1
MIC
64 N/A < 0.064 0.5 2 16
~.g/ml
Matrix Study: Oxacillin and Compound F1202 with MRSA-ATCC
The results are shown in Table 16.
Table 16.
Compound FI202
~~acillin
~,g/ml 0 16 8 4 2 I
0 3 1 1 2 2 3
64 0 0 0 0 0 0
~2 2 0 0 0 0 0
16 2 0 0 0 0 2
3 0 0 0 1 2
3 0 0 0 2
2 3 0 0 0 2 '?
1 3 0 0 0 2 3
0.5 3 0 0 1 2 3
0.25 3 0 0 1 2 3
0.125 3 0 0 2 3 3
0.064 3 0 1 2 3 3
-104-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
MIC
32 < 0.064 0.125 1 16 32
~,glml
Matrix Study: Oxacillin arad Compou~r.d FL201 with MRSA-SZJ
The results are shown in Table 17.
Table 17.
Co~cpound F1201
Oxacillin
~Cg/ml 0 32 16 8 4 2
0 3 0 1 2 2 3
256 0 0 0 0 0 0
128 1 0 0 0 0 0
64 2 0 0 0 0 0
16 3 0 0 0 0 1
4 3 0 0 0 1 1
2 3 0 0 0 I 1
1 3 0 0 0 1 1
0.5 3 0 0 0 1 2
0.25 3 0 0 1 1 2
0.125 3 0 0 1 2 2
0.064 3 0 0 1 ? 2
i' 1 ~''
2,56 i'~/~1 G 0.0640.5 16 6~,
l~glr~gl
Mats°ix Study: Oxacillirt afad Compound FL202 with MRSA-SLJ
The results are shown in Table 18.
Table 18.
C~fnpound FI X02
-105-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Oxacillin
~,g/ml 0 256 128 64 32 16
0 3 0 1 3 3 3
256 0 0 0 0 0 0
128 2 0 0 0 0 0
64 2 0 0 0 0 0
16 3 0 0 0 0 1
4 3 0 0 0 0 1
2 3 0 0 0 1 1
1 3 0 0 0 1 1
0.5 3 0 0 1 1 1
0.25 3 0 0 1 1 1
0.125 3 0 1 1 1 1
0.064 3 0 1 1 1 1
MIC
256 N/A 0.25 1 4 64
~glml
EAI~~'~E 17 ~~l~ll~Ai~~T~T O~ A~Tg'~Tl'T1E~ A~A1T'~T~T 'TEl'~-1 Al'~Y~
Amp-C (3-LsAC'1"AI~A~E~
l~aterial~ anei T~etlx~d~
The gene for AmpC ~3-lactamase (accession number P00811) eras
obtained from Escdaez°iedai~ o~li T~12 strain W3110 (American Type
Culture Collection,
I~.oclz~ille, lv'tI~). .~. ~~a/z was grown and plssaW d (f"- laclq lacF~LB
a~~ap~'::la~z~ab~l,~cI+)
was isolated via ~iagen (~alencia, CA) mini prep. The gene for AmpC was
amplified in
two pieces via polyrrmrase chain reaetion, ligated and purified by agarose gel
electrophoresis. Tlae ligated gene was inserted into a pET200 vector via a
TO1~0
reaction (Invitrogen, Carlsbad, CA). Correct gene and plasmid sequence was
verified by
standard DNA sequencing.
EL21(DE3) (Invitrogen) cells were transformed by heat-shocl~ with the
prepared plasmid. These cells were grown to an OD6oo of 0.8 at 37 °C.
Isopropylthiogalactoside (IPT(1) was added to 1 mIe~, incubation temperature
decreased
to 25 °C and the cells were grown for an additional 18 hours. After 18
hours, the E°, coli
-106-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
was pelleted by centrifugation, and discarded. The growth media was
concentrated and
dialyzed versus 100 mM Tris, pH 7Ø This solution was run through an
equilibrated Q-
resin column, and washed with excess 100 mM Tris, pH 7Ø AmpC was eluted and
purity was found to be > 95% by SDS-PAGE.
The competitive inhibition of (3-lactamase was determined
spectrophotometrically using a Varian (Walnut Creek, CA) Cary 100 UV-Visible
spectrophotometer. (3-lactamase activity was followed by measuring the
hydrolysis of
nitrocefin, [3-(2,4-dinitrostyryl)-(6R, 7R)-7-(2-thienylacetamido)-ceph-3-em-4-
carboxylic acid, E-isomer], (Calbiochem, San Diego, CA) at 486 nrn. Inhibition
assays
were performed at 25 °C in 50 mM sodium phosphate, 5 % DMS~, pH 7Ø
Typical (3-
lactamase preparations hydrolyze nitrocefm substrate from 50 to 150 s 1. Under
these
conditions, the K,~ for AmpC (3-lactamase is 250 ~M and the k°at is 975
s 1. Penicillin G
(Sigma, St. Louis, M~) was also used as a substrate to determine K~ and
Iz°s~.
Lineweaver-Burk plots were used to determine the inhibition mechanism,
and several compounds were found to inhibit competitively. For determination
of
compound inhibition constants, protein was held at 5 nM, with nitrocefin
substrate at 167
~,M and a varying inhibitor concentration. Inhibitor was added to protein and
incubated
for ten minutes before the addition of substrate. Inhibition constants were
determined by
measuring the loss of (3-lactamase activity with increasing inhibitor
concentrations and
fitting the data to standard equations for competitive inhibition.
Isothermal titration calorimetry was performed on a high-precision VP-
ITC titration calorimeter (Microcal Inc., Northampton, MA). [3-Lactamase
solutions
were titrated with inhibitors in 50 mM sodium phosphate, 2% DMS~, pH 7.0, with
j3-
lactamase con centTatiotis ranging from 15 to 25 ~~I~1I arid inhibitor
concentrations ranging
from 300 to 1000 ~1~I. The lleaa evolved from each injection was obtained by
integrating
the calorimetric signal. Heat of binding was obtained as the difference
between the heat
of reaction and the heat of inhibitor dilution. Data were analyzed using
Csrigin 7.0
(~riginLab Corporation, Northampton, MA).
These methods can also be used to express and assay recombinant TEM-1
variant of (3-lactamase.
-107-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Results
Kinetic measurements of the digestion of a natural substrate, penicillin G
and a chemically available substrate, nitrocefin are shown in Table 19.
k~~tlK,~, a
measur a of the catalytic efficiency, is larger with penicillin G as a
substrate instead of
nitrocefin.
Table 19. Kinetic characterization of the AmpC (3-lactamase.
Substrate k~~ti KM k~at~K~
penicillin G 1984 283 7.20.6
nitrocefin 97646 25328 3.90.6
1' Units are s .
2' Units are ~.M.
3' TJnits are s-1 ~,M-1.
Phenyl-boronic acids have inhibitory activity against theTEM-1 and
ArnpC ~3-lactamases. Lineweaver-lurk inhibition plots indicate competitive
inhibition.
Screening of compounds for inhibitory activity showed several compounds with
inhibitory activity in the high nanomolar to Iow micromolar range. Isothermal
titration
calorimetry was undertaken to determine the thermodynamic characteristics of
binding to
AmpC ~3-lactamase. Most compounds tested bound with favorable enthalpic
contributions, although the magnitude of the enthalpic contribution varied
greatly
between the compoulads. Several compounds bound with nM affinity.
Tlae col~y~az~rads ~~rath the highest inlnbito~-y activity end the
thernlPJdyna1111~ Co111po11ent8 of blndlng t~ .imp-~ are shown in 'Cable ~0.
also shown
are the results obtained for ~3-lactamase o,arlant TEM-1.
-108-
CA 02528587 2005-12-07
WO 2005/004799 PCT/US2004/018624
Table 20. Inhibition constants and thermodynamic parameters of compounds
versus AmpC and TEM-1 (3-lactamases
AmpC Ki dGz dHz -TdSz TEM-1 Ki' dGz dHz -TdSz
(l0a) 0.457-8590-4149 -4441 (2c) 6.7 ~-5814-1648--4166
(3f) 0.724-8151-9325 1174 (12a) 6.9 -6468 -690 -5778
(7a) 0.873-7314-9936 2622 (ln) 8.8 -5608 -1173 -4435
($a) 0.913-8190-8486 296 (lh) 9.5 -6614 -1140 -5474
(3d) 1.03 -7442-156378195 (l0a) 9.7 -7183 -982 -6201
(lla) 1.31 -7548-3114 -4434 (lx) 10.4-6655 -577 -6078
(6a) 1.53 -7757-6538 -1219 (2d) 10.9-6513 -859 -5654
F1001 1.79 -6830-644 -6186 (lb) 12 -6420 -4011 -2409
(12a) 1.94 -7231-1470 -5761 (lw) 12.7-6409 -4554 -1855
(3g) 2.69 -7356-3677 -3679 (2b) 15.2-7864 -520 -7344
(2b) 2.92 -7736-225 -7511 (ly) 15.8-6550 0 -6550
(2c) 3.68 -7115-473 -6642 (9a) 16.2-7864 446 -8310
F1201 4.45 -6566-5084 -1482 (3e) 17.1-6164 224 -6388
(lv) 5.01 -7221-104123191 (lp) 19.$-5916 -6715 799
(2d) 6.27 -70980 -7098 (2a) 22.7-7451 274 -7725
I' ~i units are ~,M.
Z' ~G, ~IH and -T~S units are cal/mol.
~,< * ays e;e aE:
The present invention is not to be limited in scope by the specific
emb~dnnents described herein. Indeed, various modifications of the invention
in
addition to those described herein will become apparent to those skilled in
the art from
the fore~c~in ~ ~lesca-ilati~an a~~d the ac,con ~panyin~ ~~~~res. such
nmda~c~tion s are
intended tca fall v~ithin the scope of the appended claims.
hTumerous references, including patents, patent applications, protocols
and various publications, are cited and discussed in the description of this
invention. The
citation and/or discussion of such references is provided merely to clarify
the description
of the present invention and is not an admission that any such reference is
"prior art" to
the invention described herein. All references cited and discussed in this
specification
are incorporated herein by reference in their entirety and to the same extent
as if each
reference vas individually incorporated by reference.
-109-
